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ABSTRACT  
   
The interaction between a virus and its host is a constant competition for supremacy. 
Both the virus and the host immune system constantly evolve mechanisms to circumvent 
one another. Vaccinia virus (VACV) infections are a prime example of this. VACV 
contains a highly conserved innate immune evasion gene, E3L, which encodes the E3 
protein composed of a Z-NA-binding domain (Z-NA BD) in the N terminus and a highly 
characterized dsRNA binding domain in the C-terminus.  Both domains of E3 have been 
found to be essential for the inhibition of antiviral states initiated by host type 1 
IFNs.   However, the mechanism by which the Z-NA-BD of E3’s N-terminus confers IFN 
resistance has yet to be established. This is partially due to conflicting evidence showing 
that the Z-NA-BD is dispensable in most cell culture systems, yet essential for 
pathogenicity in mice. Recently it has been demonstrated that programmed necrosis is an 
alternative form of cell death that can be initiated by viral infections as part of the host’s 
innate immune response to control infection.  The work presented here reveals that 
VACV has developed a mechanism to inhibit programmed necrosis. This inhibition 
occurs through utilizing E3’s N-terminus to prevent the initiation of programmed 
necrosis involving the host-encoded cellular proteins RIP3 and Z-NA-binding protein 
DAI. The inhibition of programmed necrosis has been shown to involve regions of both 
the viral and host proteins responsible for Z-NA binding through in vivo studies 
demonstrating that deletions of the Z-NA-BD in E3 correspond to an attenuation of 
pathogenicity in wild type mice that is restored in RIP3- and DAI-deficient 
models. Together these findings provide novel insight into the elusive function of the Z-
NA-binding domain of the N-terminus and its role in preventing host recognition of viral 
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infections.  Furthermore, it is demonstrated that a unique mechanism for resisting virally 
induced programmed necrosis exists.  This mechanism, specific to Z-NA binding, 
involves the inhibition of a DAI dependent form of programmed necrosis possibly by 
preventing host recognition of viral infections, and hints at the possible biological role of 
Z-NA in regulating viral infections. 
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CHAPTER 1 
OVERALL INTRODUCTION  
 
Viruses and their hosts have co-evolved in a dichotomous relationship that drives 
development strategies employed by both organisms to circumvent the defense systems 
of one another. Viruses exist and propagate as obligate intracellular pathogens due to 
their dependency on the host’s cellular machinery, which places a non-advantageous 
burden on the host organism.  Due to this, host organisms developed multiple means of 
recognizing and eliminating the viral pathogens. However, due to viruses’ dependence on 
their host’s cellular machinery to replicate for survival, they have concurrently evolved 
strategies to subvert the host’s antiviral defense mechanism to ensure continued 
propagation. Pathogenicity of a virus is heavily dependent on its ability to evade the 
host’s innate defense system.  This ability is heavily dependent on the host’s antiviral 
state generated by the actions of interferon (IFN) as well as other pro-inflammatory 
cytokines (1). 
IFNs are a group of secreted cytokines that elicit distinct antiviral effects. These 
cytokines have been known to alter the ability of a virus to survive and propagate (2). 
IFNs are systematically classified into three distinct groups.  Of these three groups, type I 
IFNs (IFN-α/β) have been the best characterized for their role of inhibiting viral 
replication as a part of the innate immune system (3) (4). The innate immune response is 
heavily dependent on IFN-α/β as the first line of defense against viral infection (5, 6) 
The generation of an antiviral state is initiated through the binding of type I IFNs 
to their ubiquitously expressed surface receptor proteins.  This binding subsequently 
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results in the activation of multiple signaling cascades, which induce the transcription of 
hundreds of IFN-stimulated genes (ISGs) (7). These ISGs are responsible for establishing 
an anti-viral state within cells through a multifaceted approach involving regulation 
mechanisms required for viral replication, enhanced production of viral detection 
systems, and increased local signaling (including IFN production) in order to prime 
uninfected neighboring cells for the impending infection.  These actions help to limit the 
virus from spreading further (1). In addition to their primary role involving innate anti-
viral responses, type I IFNs have been demonstrated to influence elements of the adaptive 
immune response through priming helper T and cytotoxic T cells, and aiding in the 
generation of an antigen-specific response (8-10).   
The production of IFN-α/β and subsequent activation of ISGs are regulated by 
host-encoded pattern recognition receptors (PRRs) which are capable of initiating 
multiple signaling cascades upon activation. These PRRs are composed of a diverse 
group of receptors capable of recognizing a broad range of pathogen-associated 
molecular patterns (PAMPs) that are distinct from host molecular patterns.  This 
recognition allows for the sensing of a pathogen in the infected cell.  During a viral 
infection involving viral genomic deoxy-ribose nucleic acid (DNA), single-stranded 
ribose nucleic acid (ssRNA), or double-stranded RNA (dsRNA) nucleic acid patterns 
specific to the virus act as critical PAMPs recognized by PRRs used for early detection 
(11).  This early detection by PRRs through the detection of PAMPs is critical, as it leads 
to the induction of IFN-α/β, which is essential for generating a systematic antiviral state. 
Following its production, IFN-α/β is secreted into the extracellular environment 
where it can implement both autocrine and paracrine signaling patterns through binding 
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to IFN-α/βRs on the cell surface to further enhance a local antiviral state. IFN-α/βRs are 
composed of IFNAR1 and IFNAR2 subunits (12-14). Binding of IFN to its receptor 
induces a signal cascade that involves Janus kinase (JAK), signal transducers, and the 
activation of transcription (STAT) pathways (14, 15), resulting in the  formation of the 
IFN-stimulated gene factor 3 (ISGF3)complex (16, 17). ISGF3 then translocates into the 
nucleus where it binds to the IFN-stimulated response element (ISRE) and induces the 
transcription of ISGs (14, 18).  
The ISGs that encode proteins with direct antiviral activity have a diverse range 
of functions including cytoskeletal remodeling, induction of apoptosis, regulation of post-
transcriptional events (splicing, mRNA editing, RNA degradation and the multiple steps 
of protein translation) and post-translational modifications.  Examples of more direct-
acting ISGs that are essential for generating an antiviral state IFN-stimulated protein of 
15 kDa(include ISG15), the GTPase myxovirus resistance 1(Mx1), ribonuclease L 
(RNaseL) and protein kinase R (PKR) (18). The majority of ISGs, however, act to prime 
cells for potential infection.  Examples of these ISGs include PRRs that detect viral 
molecules and modulate signaling pathways, or transcription factors that produce an 
amplification loop leading to increased IFN production. Together they act to induce an 
antiviral state within the cell. Initiation of an antiviral state results from the complex 
interaction of multiple ISGs and no single gene has been shown to be absolutely essential 
for every virus. The substantial gap in understanding of the essential function and 
cooperation of ISGs in regulating the innate immune response leaves a potentially 
unexplored role of IFN-α/β in regulating viral infections. 
The type 1 IFN system plays a pivotal role in generating a diverse variety of 
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antiviral responses.  One such response involves the priming of cells to undergo 
programmed cell death during infections (19).  This priming causes an antiviral effect by 
decreasing the time needed to eliminate infected cells (20-22). The steps involved in 
priming a cell for apoptosis with IFN is not limited to a single mechanism or pathway. 
Some of the well-characterized pathways include the induction of procaspase genes (18), 
PKR (10), and OAS (23, 24). The inactive pro-proteins are up-regulated and capable of 
inducing apoptosis upon activation by PAMPs such as dsRNA (23).  
Programmed cell death in infected cells establishes an effective mechanism to 
contain pathogens by limiting replication to prevent the spread of the virus.  Additionally, 
the programmed cell death simultaneously aids in the clearance of infected cells through 
phagocytes of the immune system. The critical role that programmed cell death plays in a 
host’s defense against pathogens is demonstrated through the overabundance of inhibitors 
encoded by different pathogens in order to suppress programmed cell death (22, 25-29). 
For many years, programmed cell death was synonymous with apoptosis, but 
recently alternative programmed cell death pathways have been identified as important 
regulators of the innate immune response to viral infections.  These alternative forms may 
be essential for host inhibition of viruses that encode anti-apoptotic genes (25). The field 
of virally-induced, programmed cellular death is rapidly evolving with apoptosis, 
necrosis, and pyroptosis representing the key pathways involved in innate response to 
pathogens. Each mode of cell death is characterized by particular morphological changes 
and distinctive molecular signaling pathways. Currently, defining how a cell dies is based 
on three major classification criteria composed of morphology, enzymatic characteristics, 
and immunological characteristics (30). Apoptosis is characterized by cell shrinkage, 
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nuclear condensation, chromosomal fragmentation, membrane blebbing, and the 
formation of apoptotic bodies cleared by phagocytic cells. Apoptosis is dependent on 
cysteine proteases known as caspases. These caspases are induced by external stimuli, 
such as death receptor ligation or  PRR activation, or internal stimuli that influence 
mitochondrial integrity. Caspases exist as zymogens within the cell and are activated in a 
two-stage system.  The first stage involves “initiator” caspases, such as caspases-8 and -9, 
which are induced in response to cellular signaling.  These caspases then initiate the 
second stage through the activation of the “executioner” caspases, caspases-7 and -3, 
which target cellular substrates to induce apoptotic death.  Apoptosis is classified as non-
immunogenic, based on retention of all the cellular content within the apoptotic bodies; 
this results in minimal inflammatory effects upon death. There are two known pathways 
leading to apoptosis: extrinsic and intrinsic pathways. Both of these pathways are known 
to communicate through activation of the Bcl-2 homology domain 3 (BH3)-only protein, 
Bid (31). The extrinsic pathway is triggered by the binding of extracellular death receptor 
ligands such as tumor necrosis factor (TNF), Fas ligand (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL) to their respective transmembrane receptors (30). The 
intrinsic pathway is initiated when proteins such as cytochrome c, SMAC/Diablo, and 
HtrA2/Omi are released from the mitochondrial intermembrane space into the cytosol in 
response to a variety of stresses such as chemotherapeutic drugs, UV irradiation, and 
microbial infection (31).  
In contrast to the classical non-immunogenic apoptotic death pathway, 
programmed necrosis and pyroptosis are described as highly immunogenic  because they 
release cytokines and intracellular products into the extracellular environment.  This 
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release is a result of cell membrane integrity loss and has been associated with viral 
infections (30). Enzymatically, pyroptosis is classified as a caspase-1-dependent death 
pathway. Activation of cytoplasmic procaspase-1 results in a signal cascade leading to a 
loss of plasma membrane integrity and the release of cytoplasmic contents.  This results 
in the activation of inflammatory cytokines such as IL-1β and IL-18. The activation of 
these cytokines causes cytoplasmic swelling and ultimately lysis resulting in the release 
intracellular contents (22). 
Following signaling that results in induction of pyroptosis, caspase-1 undergoes 
auto-activation through the formation of large protein complexes known as 
inflammasomes.  The inflammasome complex contains a member of the NOD-like 
receptor (NLR) family. NLRs function as sensors that detect PAMPs. Distinct 
inflammasomes are assembled depending on the infectious agent (32). Genetic studies in 
mice indicate that at least four different inflammasomes are formed in vivo: the Ipaf 
inflammasome, the Nlrp1b inflammasome, the Nlrp3 inflammasome, and a fourth 
inflammasome that is assembled upon infection with DNA viruses and some bacteria 
such as Francisella tularensis, or Listeria monocytogenes.  This fourth inflammasome 
contains the cytosolic double-stranded DNA sensor Absent In Melanoma 2 (AIM2) (32).  
Similar to pyroptosis, programmed necrosis is classified as an immunogenic 
programmed cell death that is characterized by organelle damage, cytoplasmic 
swelling, and the loss of plasma membrane integrity.  This leads to the release of 
cytoplasmic contents. Unlike other pathogen-associated forms of cell death, 
programmed necrosis occurs independent of caspases activation.  For many years, 
necroptosis was considered an accidental form of death that was outside the cell’s 
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control.  Only within the past decade has evidence emerged demonstrating that it is a 
regulated cellular death mechanism.  As of recently, some of the serine/threonine 
kinase receptor interacting proteins (RIP) have been shown to be key regulators of 
necrosis signaling (25, 33) Most of the current understanding of programmed necrosis 
comes from the TNF-driven canonical pathway termed necroptosis which involves a 
RIP1 and RIP3 interaction followed by the activation of mixed-lineage kinase domain-
like (MLKL).  Necroptosis is initiated when tumor necrosis factor (TNF) binds to the 
TNF receptor 1 (TNFR1) on the cell surface. Following TNF binding, the cytoplasmic 
portion of TNFR1 recruits the TNF receptor-associated death domain (TRADD) which 
subsequently recruits a series of proteins to form the membrane-associated complex 1.  
This complex includes RIP1, the cellular inhibitor of apoptosis protein 1 (cIAP1), 
cIAP2, TNF receptor-associated factor 2 (TRAF2), and TRAF5 (34). Upon formation 
of complex I, RIP1 undergoes polyubiquitylation by cIAP1 and cIAP2 to generate a 
scaffold for docking transforming growth factor-β-­‐activated kinase 1(TAK1); which is 
complexed with TAK1 binding protein 2 (TAB2) or TAB3 and the inhibitor of the NF-
κB kinase(IKK) complex.  Assembly of this complex activates the nuclear factor-κB 
(NF-κB) pathway which leads to the recruitment of the linear ubiquitin chain assembly 
complex (LUBAC) through the linear ubiquitin chains on RIP1. Cylindromatosis 
(CYLD) is then recruited to remove polyubiquitins from RIP1 leading to the 
destabilization of complex I.  RIP1 is then able to dissociate from the membrane 
associated complex and interact with TRADD, FAS-associated death domain (FADD), 
pro-caspase 8, and FLICE-like inhibitory proteins (FLIPs) to form complex IIa. Under 
normal cellular conditions FLIP and pro-caspase 8 form a heterodimeric caspase that 
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can cleave both RIPK1 and RIPK3 to render them inactive in order to prevent 
necroptosis.  However, in the presence of caspase inhibitors such as VACV B13R, 
RIP1 is not cleaved and remains active, which allows for the oligomerization and 
autophosphorylation of RIPK3 to occur (35). Phosphorylated RIPK3 recruits and 
phosphorylates the MLKL (35, 36). Upon phosphorylation, MLKL undergoes a 
conformational change that exposes the MLKL N-terminal domain and translocates to 
the membrane resulting in the loss of membrane integrity and ultimately cell death (37-
42). 
Even though RIP1 is critical for the activation of RIP3 through RIP homotypic 
interacting motif (RHIM) domain interactions in the canonical programmed necrosis 
pathway, RIP3 has the capacity to partner with multiple proteins that also contain 
RHIM domains to induce death. Upstream adaptors of RIP3 include RIP1, TIR-
domain-contaning adaptor-inducing interferon-β(TRIF) which is downstream of 
TLR3/4 signaling pathway (29, 43-45) and DAI (26, 46) which have all been shown to 
contain a RHIM domain. These represent important sets of adaptor proteins in innate 
signaling pathways involved in the host’s response to pathogens and further implicates 
programmed necrosis as an important host defense pathway against pathogens. 
Necroptosis has been demonstrated to result from multiple pathogens including both 
viruses and bacteria (25, 47-50).  Additionally, it has been suggested to be the default 
pathway when caspase activity is compromised (51, 52). Many viruses, including 
poxviruses and herpesviruses, inhibit caspase activity (53) and consequently have the 
potential to be susceptible to programmed necrosis. With the understanding that 
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programmed cell death is an essential component of the host defense mechanism against 
viral pathogens, it is not surprising that rapidly emerging evidence demonstrates that 
viruses have evolved mechanisms to regulate programmed necrosis in addition to 
apoptosis.  Some of the best studied examples of this can be seen in herpesviruses.  
Among these viruses, murine cytomegalovirus (MCMV) encodes suppressors of 
apoptosis as well as a M45-encoded viral inhibitor of RIP activation (vIRA) M45, which 
contains an N-terminal RHIM domain that prevents the DAI recruitment of RIP3.  This 
blocks the signal cascade leading to cell death (27, 46).  Similarly, herpes simplex viruses 
(HSV)1 and HSV2 both utilize RHIM and Caspase-8 suppression strategies through the 
uses of M45 homologs; UL39-encoded ICP6 and ICP10, respectively (48). These 
examples demonstrate that viruses employ multiple strategies to combat diverse forms of 
cell death and suggests that viral regulation of programmed necrosis is a common trend 
that extends beyond our current understanding.  
The Poxviridade family is composed of a unique cluster of large brick-shaped, 
enveloped viruses whose genome is composed of dsDNA.  This family is noted to have a 
broad host range, infecting both vertebrates and invertebrates (54, 55). Of the eight 
genera belonging to the Poxviridade family, the Orthopoxvirus genus is the most well-
characterized due to notorious members including variola virus (VARV), the causative 
agent of smallpox, as well as vaccinia virus (VACV), which is the prototypic poxvirus 
utilized to study both poxviruses and multiple facets of viral host interactions.  
Additionally, another significant member includes the recently emerged human pathogen 
monkeypox virus that caused an outbreak in the United States in 2003 (56). 
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Poxviruses are unique in their replication strategies, because their replication cycle 
occurs within the cytoplasm of their infected host, making them less reliant on host 
machinery (55).  Poxviruses’ genomes are relatively conserved, ranging from about 
134kb to more than 300 kb.  They have a general organization with highly conserved 
replication genes located within the central regions of the genome and less conserved, but 
critical, immune-evasion genes that likely correspond to host range specificity, in 
terminal regions (57).  The hairpin loop of inverted terminal repetitions connects the two 
DNA strands (58, 59). 
Viruses have evolved multiple strategies to circumvent the host’s immune system. 
VACV is a prime example of one of these viruses and has developed numerous strategies 
to subvert the host’s immune system, particularly with regard to the IFN system. VACV 
encodes virulence genes that enable the evasion of the host’s immune system. Virulence 
genes are capable of interacting with a wide range of host proteins and pathways with 
diverse effects (54, 60).  As a master regulator of the host’s IFN system, VACV has two 
proteins that have been demonstrated to directly interfere with IFN signaling (61, 62).  
These proteins, B8R and B19R (B18R in WR VACV), are soluble IFN-binding proteins 
targeting IFN-γ and IFN-α/β respectively. The IFN-binding proteins are secreted from 
infected cells and prevent IFN from being able to initiate signaling in uninfected cells, 
thereby preventing the generation of an antiviral state within neighboring cells, thus 
allowing the virus to spread (63-65) (61, 66).  Other examples of VACV virulence genes 
function to inhibit chemokine and cytokine signaling by preventing them from binding to 
their receptors IL-18 (67), TNF (68), and IL-1β (69). These virulence factors are a small 
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representation of the extensive list of mechanisms that viruses have developed to evade 
their host’s immune systems and ensure survival.  
 VACV regulation of the IFN system is not limited to the extracellular 
environment. Two well studied viral proteins, K3 and E3, have been shown to interfere 
with the intracellular IFN-signaling pathways and aid in the IFN resistance (IFNR) 
phenotype to allow for an enhanced host range (70-72).  The requirement for viruses to 
circumvent apoptosis has been well established, but more recent evidence has been 
emerging implicating alternative forms of programmed cell death as critical antiviral host 
defense mechanisms. Among the multiple immune evasion proteins encoded by VACV is 
B13R, which is an ortholg of the well characterized cowpox serpin inhibitor, CrmA. The 
serpin inhibitor functions to bind and inhibit the enzymatic activity of caspases, including 
caspase 8 and caspase 1 (73, 74). Specifically, the regulation of caspases has been shown 
to require B13R for VACV pathogenesis in mice (75); this further highlights the 
importance of the viral regulation of host cell death. However, the dynamic nature of 
programmed cell death is exemplified by the fact that VACV expresses the caspase 
inhibitor; B13R. The expression of B13R sensitizies infected MEFs  to a RIP1-dependent 
TNF-induced programmed necrotic cell death (76, 77) (78).  Insight into the significant 
role that programmed necrosis plays in host defenses during viral infections was 
demonstrated through infections with VACV in RIP3−/− mice, which resulted in higher 
viral titers and death compared to wild-type (wt) mice (25, 78). Together, this suggests 
that programmed cell death in viral infections is not limited to apoptosis and virus-
induced programmed necrosis, but may also have other forms to restrict viral infections. 
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The importance of VACV regulation of the host’s immune system involving IFN 
signaling is evident by a multidimensional approach to inhibiting it. VACV E3L is an 
essential virulence factor and one of the prime regulators of the viral host interactions. 
The significance of E3L is emphasized by the presence of a homologue in Variola that is 
nearly identical in sequence, as is found in every other member of the genus. The E3L 
gene encodes the multifunctional protein E3.  Prior studies have demonstrated that E3 is 
essential for IFNR, host range, and pathogenesis.  While VACV with wt E3 is highly 
IFNR, VACV deleted of E3L (VACVΔE3L) is IFN-sensitive in multiple cell lines (70, 
79, 80), has a restricted host range (70, 72, 80), and is highly attenuated in mouse models 
(81).  
It has been demonstrated in a cell culture system that E3 is required to prevent the 
activation of both the PKR and OAS-RNase L pathways. Infections in the absence of E3 
result in the activation of PKR and subsequent phosphorylation of eIF2α leading to an 
arrest of translation (82).  Activation of the OAS-RNase L pathway following infection 
with VACVΔE3L results in the degradation of ribosomal RNA (70). Additionally, it has 
been suggested that the restricted host range of VACVΔE3L is linked to activation of 
systems leading to the induction of apoptosis typically inhibited in wt VACV.   
The E3L gene codes for two variants E3: a full length p25 form and a truncated 
p20 version. The p25 form of E3 is a 190 amino-acid-long protein and contains two 
highly conserved domains: an amino-terminal Z form nucleic acid-binding domain (Z-
NA-BD) and a carboxyl-terminal dsRNA-binding domain (dsRNA-BD) (83, 84). The 
truncated p20 form of E3 occurs from leaky scanning, resulting in translation initiation 
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occurring at the second downstream start codon which omits the first 37 amino acids of 
the protein (85).  
   The E3 protein plays a pivotal role in the immune evasion of a host’s defenses 
and is dependent on the presence of both domains.  The dsRNA-BD located in the 
carboxyl-terminus(C-terminus) of E3 is highly conserved within the subfamily 
Chordopoxvirinae (86).  The primary function of the C-terminus is to bind the dsRNA 
that is a byproduct of viral transcription in order to sequester it from PRRs (80, 87) (85, 
88, 89) (90).  The dsRNA-BD is essential for host range, IFNR, and full pathogenesis in 
animal models (80, 81, 87).  Truncations of the last 26 amino acids from the C-terminus 
(VACV-E3L∆26C)  results in a highly attenuated virus that is apathogenic in the 
C57BL6 mouse model equivalent to VACV∆E3L (81) and induces apoptosis in HeLa 
cells (91).  
The N-terminal Z-NA-BD of E3 is fairly well conserved among many members 
of the subfamily Chordopoxvirinae and highly conserved in the Orthopoxvirus genus. 
The Z-NA-BD shares homology with a family of IFN-inducible vertebrate proteins 
known to bind Z-form DNA including the DNA-dependent activator of IFN-regulatory 
factors (DAI) (also known as DLM-1 or ZBP-1) (92, 93) and adenosine deaminase that 
acts on RNA 1 (ADAR1) (94, 95). The Z-NA binding (Zα) motif was originally 
described in ADAR1. ADAR1 was shown to have a specificity for binding to left-handed 
Z-DNA (96-101) and was later identified in DAI as well as the E3 protein of VACV (96, 
102). The crystal structure of the Zα of ADAR1 (103) and DAI (102) demonstrating the 
conserved Z-NA binding motifs found within this family. 
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The Zα motif is based on a common configuration composed of a winged helix-
turn-helix motif (104). While this configuration is also common among B-DNA binding 
motifs, the crystal structures of the Zα motifs of both ADAR1 and DAI (102, 103) show 
that nucleic acid binding is specific to the zig-zag conformation associated with the 
backbone of Z-DNA.  The structure of the Zα motif of the Z-NA-binding protein family 
are very similar despite a lack of conservation of the of amino acid sequence outside the 
key residues that make contact with the Z-DNA (103).  A protein sequence alignment of 
E3 and the Zα domain of ADAR1 shows that E3 retains seven of the nine conserved 
residues necessary for binding to Z-DNA and is capable of binding  to Z-DNA in vitro 
(105, 106).   
ADAR1  is an ISG composed of 3 distinct regions, 1) two nucleic acid-binding 
domains, Zα and Zβ, located in the N-terminus, 2) three dsRNA-BDs located in the 
central region of the protein, and 3) a deaminase catalytic domain in the C-terminal (96). 
It plays a role in the post-translational editing of RNA by deaminating adenosine to 
inosine in dsRNA complexes to promote the unwinding of dsRNA (95, 107).   
DAI is also an ISG that is composed of the Zα motif that is separated by an 
intervening linker from a second nucleic acid binding domain called Zβ, located in the N-
terminus.  This domain is followed by a true RIP Homotypic Interacting Motif (RHIM) 
domain with an overlapping B-DNA-BD and an additional two RHIM like domains 
located in the C-terminus.  DAI has been identified to function as a cytosolic DNA sensor 
and an activator of innate immune responses through the activation of IRF3 and 
subsequent induction of IFNα/β production following stimulation with B-DNA (108) 
Recently, DAI was identified as an important player in the field of virally induced 
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programmed necrosis through utilizing the C-terminal RHIM domain to regulate 
programmed necrosis in MCMV. 
 The function of the N-terminal domain of E3 corresponds to an ability to bind Z-
DNA. The Zα of both ADAR1 and DAI can complement the deletion of the N-terminal 
of E3 despite the lack of homology outside the Z-NA binding residues (105). 
Additionally, mutations that decrease affinity for Z-DNA binding within the Zα 
corresponds to a reduction of pathogenesis (105). 
While the significance of the N-terminus of E3 can be inferred from its 
conservation among the Orthopoxviruses, understanding the biological function of the Z-
NA-BD has been inhibited by the lack of a cell culture system that demonstrates a 
phenotype that is not redundant to that of a virus containing the C-terminus only.  The 
initial in vitro studies utilizing a truncation mutant with the first 83 amino acids deleted 
from the N-terminus (VACV-E3L∆83N) indicated that this domain is non-essential to 
host range or IFNR with phenotypes equivalent to wt VACV (80, 109).  The one variation 
between wt VACV and VACV-E3L∆83N noted in vitro was that at late times post 
infection in HeLa cells, VACV-E3L∆83N in contrast to wt VACV was able to induce the 
phosphorylation of eIF2α and PKR.  However, unlike VACV-∆E3L, theses 
phosphorylation events do not impair the virus's ability to replicate (110). In vivo  studies 
conducted in C57BL6 mouse models have now confirmed suspicions that the N-terminus 
is in fact essential for both full pathogenesis and neurovirulance, as demonstrated by a 
1000-fold reduction in pathogenisis in animals compared to wt VACV (111). The loss in 
pathogenicity mirrors the phenotype identified in culture showing that the N-terminus is 
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not required for replication but is instead associated with restricted spread beyond the site 
of infection (111). 
Recently it has been demonstrated that the N-terminal domain of E3 is necessary 
for full IFNR demonstrated by a rescue of pathogenesis to wt VACV levels in interferon-
α/β receptor-knockout mice (IFNR-/-) (81, 111, 112). Additionally, through utilizing 
mouse embryo fibroblasts (MEFs), it was found that IFNR corresponds to the activation 
of PKR in the absence of the Z-NA-BD (112). However, pathogenesis of VACV-
E3L∆83N is not restored in PKR-/- mice. Together these conflicting sets of data suggest 
that additional systems may be responsible for the attenuated phenotypes observed. 
This study focused on the role that IFN plays in regulating programmed cell 
death. In Chapter 2 we investigate the function of the N-terminus of E3 in regulating a 
programmed necrotic death.  In Chapter 3 the role of Z-NA binding by the host DAI and 
VACV E3 are evaluated in the role of regulating programmed necrosis.  
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Figure 1.  A basic schematic of the IFN resistance protein E3 in wt VACV. E3 is a 
25 kDa  protein that has two domains. In the N terminal is the Z-NA-binding domain 
that can bind to Z-form nucleic acid including Z-DNA or Z-RNA. In the C-terminal is 
the dsRNA-binding domain that is responsible for the sequestering of dsRNA done by 
VACV in the infected cells. Both domains have been shown to be responsible for full 
pathogenesis in mice, for full inhibition of PKR in both mice and in cells in culture, 
and for full IFN resistance in mice. The two main forms of E3 that wt VACV 
generates is depicted with full length E3 at the top followed by the truncated p20 E3 
naturally produced.  
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Figure 2. E3 sequence homology in the orthopox family N-terminal domain. 
Yellow indicates highly conserved amino acids. Green indicates 100% conserved 
residues. Orange star symbolizes residues  that interact with Z-form nucleic acids 
and blue circles are residues that interact with PKR. Reference sequences used for 
alignment include:  Vaccina virus WR gb|AAO89338.1 ,Variola virus 
gb|ABG45643.1, Ectromelia virus  ref|NP_671561.1, Cowpox virus 
emb|CRL86821.1, Raccoonpox ref|YP_009143366.1, Horsepox gb|ABH08163.1, 
Camelpox gb|ABH08163.1, Swinepox ref|NP_570192.1, Sheeppox 
ref|NP_659606.1, Deerpox ref|YP_002302383.1. 
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Figure 3.  A schematic depicting the three major programmed cell death 
pathways.  Apoptosis is shown on the left followed by necroptosis in the middle and 
pyroptosis on the right. Apoptosis signals through both intrinsic and extrinsic signaling 
cascades and is enzymatically dependent on a series of initiator and executioner  
caspases. Classical necroptosis signals through the TFN death receptor and functions 
independently of caspases through the use of RIP 1 and RIP3 leading to the activation 
of MLKL. Pyroptosis utilizes non-classical caspases activated through the formation of 
an inflammasome.   
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Figure 4. Canonical and noncanonical programmed necrosis pathway. 
Canonical activation of necroptosis uses RIP1 as an adaptor protein  for the 
recruitment and activation RIP3 downstream of TNF family death receptors 
(TNFR1, Fas, TRAIL).  Noncanonical activation of programmed necrosis via DAI 
was previously demonstrated in MCMV infection or via TRIF, which is 
downstream of TLR3 and TLR4 activation, driving recruitment and activation of 
RIP3.  In all forms of RHIM-dependent activation of RIP3, RIP3 activation through 
phosphorylation results in  RIP3-dependent recruitment and phosphorylation of 
MLKL leading to plasma membrane leakage and other features of programmed 
necrosis.  
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CHAPTER 2 
THE E3 AMINO TERMINUS OF VACCINIA VIRUS IS REQUIRED TO INHIBIT 
INTERFERON REGULATED PROGRAMMED NECROSIS 
 
ABSTRACT 
 
 
Programmed necrosis is an alternative form of programmed cell death that 
functions as part of the innate immune response initiated by viral infections.  It occurs 
when caspase activity is inhibited and aids in the immune response’s clearance of virus-
infected host cells. Vaccinia virus (VACV) encodes both a caspase inhibitor and the 
essential IFN resistance (IFNR) gene, E3L.  This gene encodes the protein, E3, which 
contains a Z-NA-binding domain (Z-NA-BD) in the N-terminus and a dsRNA-binding 
domain in the C-terminus.  The protein is responsible for inhibiting the host type I 
interferon (IFN) pathway and is required for full pathogenesis.  In the past, the Z-NA-BD 
of the protein has been shown to be dispensable for replication and IFNR in most culture 
cells, yet critical for pathogenicity in mice models.  In addition to being essential for in 
vivo models, the N-terminus containing the Z-NA-BD has been found to be highly 
conserved within poxviruses, indicating that it has has an essential function needed by the 
virus. Characterization at a molecular level has been limited due to lack of evidence 
demonstrating a specific molecular or biochemical function of the N-terminus. In this 
study we identify a cell culture system using L929 cells that demonstrated type I IFN 
sensitivity of VACV lacking the N-terminus of the E3 protein  mirroring the previously 
in vivo studies. IFN sensitivity of VACV lacking the N-terminus of E3 is demonstrated 
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by a reduction of plaquing efficiency and the rapid induction of cell death. Furthermore, 
our research indicates that the N-terminus is required to inhibit IFN-primed, RIP3-
dependent cell death through the phosphorylation of MLKL, independent of RIP1. In 
vivo, the highly attenuated phenotype VACV which encode for E3 deleted of the N-
terminus in wild type (wt) mice is is reversed in a RIP3-deficient mouse model. Overall 
this work demonstrates that the N-terminal domain of E3 is required to inhibit type I IFN-
primed, virally-induced, non-canonical, programmed necrosis.  
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INTRODUCTION 
Type I interferons (IFNs) (IFN-α/β) are potent cytokines that function as a major 
component of the innate immune system and prohibit viral replication and spread. In 
response to viral infections, most cells are able to rapidly induce the synthesis of IFN and 
generate an antiviral state (105). IFN-α/β induce an antiviral state by binding to their 
IFN-α/β receptor located on the surfaces of cells. Binding results in the initiation of a 
signal cascade utilizing the JAK/STAT pathway, ultimately resulting in the upregulation 
of IFN-stimulated genes (ISGs) (18, 113). Hundreds of ISGs are upregulated in response 
to IFN, some of which function to prime the cells into an antiviral state including 
multiple Pattern Recognition Receptors (PRRs). 
VACV is an IFN-resistant dsDNA virus that is unique in its ability to replicate in 
the cytoplasm of its infected host. Due to its unique mechanism of replication, it has 
evolved to evade the host immune response with approximately one third of its genome 
dedicated to virulence factors. VACV depends on its ability to circumvent the host’s IFN 
system. A major contributor to the VACV IFN-resistant phenotype is the dsRNA binding 
protein E3. VACV deleted of E3L (VACVΔE3L) is IFN sensitive in cells typically noted 
for their permissive nature, including rabbit kidney RK-13 cells and human Huh7 cells 
(70, 79, 80). 
The IFN-resistant phenotype has primarily been attributed to inhibition of Protein 
Kinase R (PKR). Previous studies demonstrated that RNA interference against PKR in 
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Huh7 cells reversed the IFN-sensitive phenotype of VACVΔE3L. The ability to inhibit 
PKR primarily maps to the C-terminus of E3, which encodes a ds-RNA-binding domain 
(dsRBD) (80) . 
Characterizing the function of E3’s second highly conserved domain located in 
the N-terminus of E3 has been problematic.  In vitro, the N-terminus is completely 
dispensable for IFN resistance and replicationin most cells (80, 114), but is necessary for 
full pathogenesis in mice (81, 111). In mouse models, the N-terminus is required for 
spread of infection (81) and neurovirulence (111). Recently, the highly attenuated 
phenotype of VACV deleted of the N-terminus (VACVE3LΔ83N) seen in mouse models 
was demonstrated to be due to IFN sensitivity as seen by a restoration of pathogenesis in 
mice deleted of the type I IFN receptors (IFN-α/βR−/− mice) (112). 
Using 129MEFs, IFN sensitivity was found to correspond to VACV-E3LΔ83N 
signal induction of antiviral pathways by PKR, which is an IFN-inducible PRR that 
recognizes dsRNA. 129 MEFs infected with VACVE3LΔ83N induced the 
phosphorylation of the translation initiation factor eIF2α leading to protein synthesis 
shutdown. IFN resistance was restored in PKR−/− MEFs by knockdown of PKR in MEFs 
(112). However, Pathogenesis of VACV-E3LΔ83N was not restored in PKR-/- mice, 
suggesting that PKR was not essential for inhibiting VACV-E3LΔ83N  pathogenesis in 
mice.  
Despite significant evidence that the N-terminus is required for IFN resistance, 
the molecular function unique to this domain remains elusive, as a system has not been 
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established that is consistent with the IFN-sensitive phenotype in mouse models. The lack 
of a consistent phenotype between in vivo and in vitro models suggests that cells may be 
utilizing an alternative IFN-regulated cell mechanism to inhibit replication of VACV-
E3LΔ83N.  
The type 1 IFN system plays a huge role in generating a large variety of antiviral 
responses.  One such response is the priming of programmed cell death during infections. 
In the current generalized model of programmed cell death, apoptosis represents the 
predominate cell death pathway with other distinct death pathways acting in a 
cooperative or substitutive fashion. Recently, alternative cellular death mechanisms have 
come into focus with regard to viral infections: necroptosis and pyroptosis. New studies 
has shown that alternative death pathways may be essential for inhibition of viruses that 
encode anti-apoptotic genes such those seen in VACV(25).  
Programmed necrosis has recently been demonstrated to function as an alternate 
host defense pathway initiated during the course of a viral infection, specifically, when 
caspase function is inhibited in susceptible cells (51, 52). Alternative programmed death 
is required during many viral infections because many viruses encode caspase inhibitors, 
including poxviruses and herpesviruses (53).  These inhibitors prevent the cell from 
signaling through caspase-dependent pathways to induce death.  In infections that inhibit 
caspase functions, programmed necrosis is initiated in a caspase-independent manor in 
order to bypass the pathogen regulation of cell death.  Initiation of programmed necrosis 
has been demonstrated to play a significant role in antiviral host defense by reducing viral 
replication and clearing virally infected cells (25, 27). 
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Programmed necrosis is an inflammatory form of programmed cell death. 
Activation leads to the induction of a signal transduction pathway involving RIP3 and the 
downstream pseudokinase known as mixed lineage kinase-like (MLKL). Activation of 
MLKL leads to defects in membrane integrity (40, 42). The classical programmed 
necrosis pathway induces death following TNF binding toclassical death receptors (DRs), 
under caspase-inhibited conditions, and results in the formation of a RIP1-RIP3 complex 
called a necrosome.  The necrosome then interacts through RIP homotypic interaction 
motif (RHIM) domains and employs the kinase function of both proteins (25, 27, 53, 115, 
116). The role of RIP3 in programmed necrosis is not limited to the classical pathway but 
is also required for programmed necrosis initiation through non-classical pathways such 
as IFN-regulated PRR activation (43, 115, 116).  
As with most host defense mechanisms, viruses have adapted to regulate the 
programmed necrosis to bypass the host and allow for the infection to continue.  An 
example of this has been demonstrated in Murine Cytomegalovirus (MCMV) (27, 46).  In 
MCMV infections, RIP3 can complex with DAI, through their RHIM domains, in the 
signaling cascade to induce programmed necrosis.  To prevent the induction of 
programmed necrosis, MCMV encodes an M45 protein which acts as a viral inhibitor of 
RIP activation (vIRA).  M45 functions by sequestering RIP3, impeding the signal 
transduction that induces cytokine activation and programmed necrosis (28, 44, 117, 
118).BecauseVACV has the capacity to produce a caspase inhibitor, it is likely that it 
must also have the capacity to inhibit the induction of programmed necrosis.  In this 
study, the role of the N-terminus of E3 on the inhibition of a virally-induced necroptosis 
that is regulated by type I IFN is investigated.   
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MATERIALS AND METHODS 
 
 
Cells and viruses. L929 cells were maintained in minimum essential medium 
(MEM) supplemented with 5% fetal bovine serum (FBS) (HyClone) and not allowed to 
exceed 7 passages. HEK293T cells were maintained in Dulbecco's modified minimum 
essential medium (D-MEM) supplemented with 10% FBS. The Western Reserve (WR) 
strain of wt VACV and virus mutants deleted of the full E3L gene (VACVΔE3L), the 
coding for the N-terminal 83 amino acids of E3 (VACVE3LΔ83N), or the coding for the 
N-terminal 37amino acids of E3 (VACVE3LΔ37N) were generated previously (81). All 
virus stocks were generated in BHK cells. Crude lysates were purified by pelleting 
through a 36% sucrose pad.  
Interferon Resistance Evaluation by Plaque Reduction.  6-well plates of 
subconfluent L929 cell monolayers were treated with 0-300 U/mL of mouse IFN-α 
(Calbiochem) 18 h prior to infection. Cells were then infected with 1x102 PFU of either 
WR strain of wt VACV  or VACVE3LΔ83N  virus diluted in MEM containing 2% FBS. 
Cell monolayers were infected with 100 µL of virus after aspirating the media off the 
dishes. Cells were incubated at 37oC, 5% CO2 for 1 hour, with rocking every 10 minutes.  
After 1 hour cells were overlaid with MEM containing 5% FBS, and incubated at 37ºC.  
48-72 hours post infection (hpi), upon formation of plaques, the monolayers were stained 
with crystal violet (0.5 % in 20% ethanol) and plaques were counted.  The reduction in 
the number of plaques was recorded as a percentage of plaques in the absence of 
interferon and was plotted against increasing units of interferon.  
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Protein synthesis shut off and protein loss assay. 50% confluent L929 cell 
monolayers in 60 mm dishes were infected with WR strains of wt VACV or VACVΔE3L 
or E3L N-terminal mutants (VACVE3LΔ83N or VACVE3LΔ37N) at an MOI of 5. At 30 
minutes prior to indicated time of radiolabeling, cells were washed twice with PBS to 
remove all media containing methionine and were subsequently overlaid with methionine 
free DMEM (CellGro) for 30 minutes at 37°C. Following starvation of methionine, the 
cells were incubated for 30 min at 37°C with labeling media containing 50 µCi 
[35S]methionine/ml (800 Ci/mmol, Perkin Elmer)  to label newly synthesized proteins. 
Cells were washed twice with pre-warmed PBS, then pelleted and lysed in 100 µL of 1X 
SDS [62.5 mM Tris-Cl, 10% glycerol, 2% SDS, 0.0005% bromophenol blue, 0.1% 2-
mercaptoethanol, 1X Halt Protease and Phosphotase Inhibitor Cocktail (Pierce Thermo 
Scientific)]. Protein lysates were isolated utilizing QIAshredder columns (Qiagen) by 
spinning lysates in columns at 16,000xg for 2 minutes at 4°C. Samples were stored at -
80°C. The samples were boiled for 5 minutes and separated on denaturing 10% SDS-
PAGE gels. The gels were stained for total protein levels with Coomassie staining 
solution (0.1% Coomassie Brilliant Blue R-250, 40% methanol and 10% glacial acetic 
acid) for 30 minutes.The gels were then destained with destaining solution (40% 
methanol and 10% glacial acetic acid) three times, each 20 minutes, and were incubated 
overnight in 10% glacial acetic acid to remove any residual stain.  Radiolabeled proteins 
were visualized by autoradiography with a 24-hour film exposure at -20°C. 
Live imaging of L929 infected cells. L929 cells were plates in 12 well CytoOne 
tissue culture treated plates(USA Scientific) and pre-treated with 100 U/mL of mouse 
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IFN-α (Calbiochem) for 18 h prior to infection. A live nuclear stain was applied using 
Hoechst 33342 (2'-[4-ethoxyphenyl]-5-[4-methyl-1-piperazinyl]-2,5'-bi-1H-
benzimidazole) and incubated 15 minutes prior to infection. Cells were infected with an 
MOI of 5 with either wt VACV or VACVE3LΔ83N as described above. For images used 
to evaluate alterations in morphology, infected cells were incubated for an additional 5 
hours and imaged with an EVOS™ FL Auto Imaging System ( Invitrogen™). For time-
lapse imaging, cells were overlaid with MEM media containing 1µM  
SYTOX® Green nucleic acid stain (Thermo Fisher Scientific). Cells were incubated at 
37°C with 5% CO2-supplemented air on an EVOS™ FL Auto Imaging 
System(Invitrogen™) with onstage incubator system and an image was taken every 2 
minutes for 5 hours.  
L929 Viability Assay.  Viability was assessed with a SYTOX® nuclear stain 
uptake assay or by a CellTiter-Glo® Luminescent Cell Viability Assay(Promega). For 
SYTOX® nuclear stain uptake assay L929 cells were plates in 12 well CytoOne tissue 
culture treated plates(USA Scientific) and pre-treated with 100 U/mL of mouse IFN-α 
(Calbiochem), for 18 h, prior to infection. A live nuclear stain was applied using Hoechst 
33342 and incubated 15 minutes prior to infection. Cells were infected with an MOI of 5 
with either wt VACV or VACVE3LΔ83N as described above. At 5 hpi, 
SYTOX® Green nucleic acid stain (Thermo Fisher Scientific) was added to the media at 
a concentration of 1µM and allowed to incubate for 15 minutes. Cells were then 
evaluated for viability by imaging a total of 10 fields with a 20X objective, using 
EVOS™ FL Auto Imaging System ( Invitrogen™) to evaluate. Percent viability was 
determined by comparing the number of cells that had SYTOX® incorporation to total 
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number of cells.  For CellTiter-Glo® Luminescent Cell Viability Assay, L929 cells were 
plated in a 96-well plate and pre-treated with 100 U/mL of mouse IFN-α (Calbiochem) 
for 18 hours, then infected at an MOI of 5. At 12 hpi, CellTiter-Glo reagent was added 
according to manufacturer’s recommendations and incubated at room temperature for 30 
minutes. Results were read on a GloMax® 96 Microplate Luminometer(Promega) as 
relative luminesce units (RLU). 
Inhibitors and Treatment of cells: All inhibitor treatments were applied for 1 
hour prior to infections. Inhibitors were also added to the media used to infect and 
overlay cells.  Mock treatments consisted of the addition of DMSO (Sigma) at the 
volume used in corresponding treatments. Requirement for caspase involvement in cell 
death was evaluated by treating cells with the pan-caspase inhibitor Z VAD-FMK (ZVD) 
(ApexBio) at 100µM. Evaluation of the requirement of RIP proteins were evaluated with 
the use of GSK inhibitors at 3µM. N-(6-(Isopropylsulfonyl)quinolin-4-
yl)benzo[d]thiazol-5-amine (GSK872, GlaxoSmithKline) was used to inhibit RIP3 
activity.  3-Benzothiazol-5-yl-7-(2,5-dimethyl-2H-pyrazol-3-yl)-thieno[3,2-c]pyridin-4-
ylamine (GSK 843GlaxoSmithKline) was used to evaluate the requirement for  kinase 
activity of RIP3. 2,2-Dimethyl-1-(5(S)-phenyl-4,5-dihydro-pyrazol-1-yl)-propan-1-one 
(GSK963, GlaxoSmithKline) was used to determine the requirement of RIP1 activity. 
Cells used as a positive control for programmed necrosis were treated with mouse TNF-α 
(Sigma)  at 20ng/ml following a 1-hour pretreatment with 100µM of ZVD (ApexBio).  
Protein Extraction and Western immunoblot analysis. L929 cells were pre-
treated with 100 U/mL of mouse IFN-α (Calbiochem) for 18 hours, prior to infection, and 
were infected with viruses at an MOI of 5. At 4 HPI, cells were scraped into the medium 
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and subsequently pelleted by centrifugation at 500 × g for 10 minutes at 4°C. The 
supernatant was removed and the cells were washed, pelleted, and washed a second time 
with ice-cold PBS. Cell extracts were then obtained by lysing the cells in complete Triton 
X lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na 2EDTA, 1 mM 
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
mM Na3VO4, and 1X Halt Protease and Phosphotase Inhibitor Cocktail, Pierce Thermo 
Scientific) and incubated on ice for 5 minutes. Samples were centrifuged at 15,000 × g 
for 20 minutes at 4°C. Supernatant was collected and SDS protein loading dye (3X) was 
added. For samples used for MLKL aggregation, cells were scraped and pelleted as 
described above but lysed in100 µL of 1X SDS (62.5 mM Tris-Cl, 10% glycerol, 2% 
SDS, 0.0005% bromphenol blue, 1X Halt Protease and Phosphotase Inhibitor Cocktail, 
Pierce Thermo Scientific) without 2-mercaptoethanol. Lysates were transferred into 
QIAshredder columns (Qiagen), spun at 16,000xg for 2 minutes at 4°C. All samples were 
stored at -80°C. Samples were boiled for 5 minutes, separated on a denaturing 10% SDS-
PAGE gel, and then transferred onto a nitrocellulose membrane at 100 volts for 75 
minutes in 10 mM CAPS, pH 11 with 20% methanol. Following transfer, the membrane 
was incubated in blocking buffer (140 mM NaCl, 3 mM KCl, 20 mM Tris [pH 7.8], 
0.05% Tween 20, 3% nonfat milk) for 1 hour at room temperature. Rabbit polyclonal 
antibodies were used to detect P-MLKL (Abcam 1:2000) and total MLKL (Abcam 
1:1000), and mouse monoclonal antibodies were used to detect glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Primary antibodies were diluted in blocking buffer 
and blots were exposed to antibodies overnight. Secondary goat anti-rabbit IgG 
conjugated to horseradish peroxidase (1:5000, Santa Cruz) or anti-mouse IgG conjugated 
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to horseradish peroxidase (1:5000, Santa Cruz) were incubated at room temperature for 1 
hour. Immunoreactive bands were visualized by chemiluminescent development using 
SuperSignal West Dura Duration substrate (Pierce Biotechnology).  
Intranasal infections of mice. Anesthesia and infections were carried out as 
previously described (112). Briefly, wt C57BL/6 and RIP3−/− mice were anesthetized 
with a ketamine cocktail containing 37.5 mg/ml ketamine (Lloyd Laboratories, 
Shenandoah, IA), 7.5 mg/ml xylazine (Vedco, St. Joseph, MO), and 2.5 mg/ml 
acepromazine maleate (Fort Dodge Laboratories, Fort Dodge, IA) at the age of 8 to 10 
weeks. Intraperitoneal injection (IP) of anesthesia was given at a dose of 1 µl per gram of 
body weight. Anesthetized mice were infected with 5 µl containing 106 PFU of either 
WR strain of wt VACV or VACVE3LΔ83N virus intranasally. Mice were monitored 
daily for clinical signs and given a clinical score based on weight loss, lethargy, 
respiratory distress, declines in general appearance (scuffed), and eye infections. Each 
clinical sign was given a score of 1 to 5 with 5 representing severe symptomology. 
Weight loss score was determined by the percent of their original weight with 100% of 
original weight receiving a score of 0; 93.7 to 99.9% given a score of 1; 86.2 to 93.2% 
given a score of 2; 78.6 to 86.1% given a score of 3;71.0 to 78.5% given a score of 4; 
70% and below was given a score of 5 (81, 111). All mice were euthanized by 
asphyxiation using CO2 when any mouse dropped below 30% of their initial weight or 
reached a clinical score above 25.  
Statistics. Statistical analysis was done by using a two-tailed, unpaired T test. P 
values of p<0.001 were represented as ***, p<0.01 were represented as **,  p<0.05 were 
represented as * and no significance (N.S.) was used to represent p>0.05. In order to 
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determine the model of regression for cell viability, relative viability was transformed 
logarithmically,then subjected to a  linear regression analysis.  Statistical significance in 
this analysis meant that regression was occurring in a logarithmic manner.    
  34 
RESULTS  
E3, the multifunctional protein encoded by VACV, plays an essential role in 
counteracting the host innate immune system. One of its primary functions involves 
inhibition of the downstream type I IFN effects. While E3’s C-terminus has been 
extensively characterized for its role as a dsRNA-binding molecule, the same level of 
characterization for the N-terminal Z-NA-binding domain has not been possible. 
Limitations in characterizing the biological role of the N-terminus are primarily due to a 
lack of viable cell culture systems in which any significant function of the protein can be 
observed. Specifically, no systems have been able to identify a biological role for the 
protein in inhibiting interferon responses, which are essential in mouse models (112). In 
an attempt to further evaluate the function of the N-terminus, our lab has discovered a 
cell culture system that mirrors the need for a functional N-terminus in inhibiting the 
interferon response, previously observed in mouse models, through the use of a murine 
fibroblast cell line (L929).  
The N-terminus is required for type I IFN resistance in L929 cells. L929 cells 
were pretreated with increasing amounts of mouse IFN-α prior to infection. 
Subsequently, cells were infected with equivalent plaque forming units (PFUs) of 
wtVACV or VACV expressing E3 with a truncated N-terminus (VACV-E3LΔ83N) 
(111). As seen in figure 6, plaque formation by wtVACV is resistant to IFN-α 
pretreatment, but the plaque formation ofVACV-E3LΔ83N was IFN-α sensitivity.  This 
increased sensitivity caused the percent of original PFUs to decrease in a with increasing 
IFN-α U/mL treatments until a treatment of just over 100 U/mL, where no plaque 
formation was observed. This demonstrated that the N-terminus of E3 is, in fact, essential 
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for VACV circumvention of the antiviral state induced by type 1 IFNs, similar to the 
results observed in mouse models.  
Global reduction of protein in VACV-E3LΔ83N-infected L929 cells in an IFN-
dependent manner.  One of the most common ways that IFN inhibits virus replication is 
by inhibiting viral protein synthesis.  In an attempt to evaluate the relationship between 
protein synthesis in L929 cells pretreated with mouse IFN-α and VACV E3 N-terminal 
mutants, newly synthesized proteins were labelled with a pulse of [35S]methionine at 
various times post-infection. These proteins were then separated by SDS-PAGE and 
visualized by autoradiograph (Fig.7A). As expected, wtVACV is able to circumvent the 
inhibition viral protein sysnthesis the E3 sequestering dsRNA and VACVΔE3L resulted 
in rapid protein synthesis shutdown due to the absence of E3(110, 112). Inhibition of new 
protein synthesis is demonstrated by the lack of isotope incorporation with the retention 
of total cellular proteins visualized by Coomassie staining (Fig.7B). The autoradiographs 
also show that, at later times post-infection, the lanes with lysates of cells pretreated with 
IFN-α and infected VACV-E3LΔ83N did not have isotope-labeled protein present. 
However, the lack of labeled protein within these lanes does not necessarily indicate 
protein synthesis shutdown due to the corresponding failure to recover proteins from 
IFN-treated, VACV-E3LΔ83N -infected L929 cells (Fig.7B), as visualized in the stained 
gels. This absence of total protein on the stained gels does not fit the classical pattern of 
protein synthesis shutdown through eIF2-α.  The loss of total viral and cellular proteins 
suggests that there is an alternative cellular process occurring. More significant, this 
process is primed by IFN-α treatment, and occurs only in the absence of a functional N-
terminus on VACV’s E3. 
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Type I interferon sensitivity in N-terminal mutants result in alterations of cell 
morphology. In order to gain insight into the IFN-α-dependent process that leads to total 
protein loss following infections with VACV expressing E3 N-terminal mutants, live 
imaging was conducted. L929 cells were pretreated with mouse IFN-α and infected with 
wt or with VACV expressing  E3 N-terminal mutants. Observations captured through live 
imaging showed that L929 cells pretreated with IFN and infected with VACV-E3LΔ83N 
undergo unique morphological changes not seen in the other conditions (Fig. 8). Starting 
at approximately 4HPI, pretreated L929 cells infected with E3LΔ83N progressively 
underwent cytoplasmic enlargement and cytoplasmic membrane disruption, not seen in 
cells infected with wtVACV, irrespective of IFN treatment. The cellular swelling and 
cytoplasmic membrane disruption suggests that an IFN-α dependent alternative process 
of programmed cell death that does not fit the classical morphology of apoptosis may 
occur in cells infected with E3L N-terminal mutants. This loss of cellular membrane 
integrity and cytoplasmic enlargement may represent the cellular process responsible for 
the global loss of recovery of proteins shown earlier. 
IFN-α sensitivity results in a rapid death characterized by membrane 
permeability. L929 cells that were pretreated with IFN-α and infected with E3 N-
terminal mutants suggests that total protein loss is due to rapid activation of programmed 
cell death that results in loss of membrane integrity. In order to evaluate if the 
morphology results from a cellular death mechanism, a cell viability assay was performed 
using a membrane-impermeable nuclear stain. This assay demonstrated that L929 cells 
pretreated with IFN-α and infected with VACV expressing the N-terminal mutant results 
in increased cellular death compared to an uninfected control and cells infected with wt 
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VACV (Fig. 9). These results are apparent from SYTOX dye uptake, which indicates 
membrane permeability.  Combining these results with the live imaging results suggests 
that the morphological changes correlate with programmed cell death.   
 IFN-α primed death is dependent on RIP3 and is caspase independent. 
Programmed cell death pathways can be broadly separated into those that are caspase 
dependent (apoptosis and pyroptosis) and those that are caspase independent 
(necroptosis, or programmed necrosis). To determine if del83N-induced death was 
caspase dependent,  we asked if cell death was sensitive to a membrane permeable, pan-
caspase inhibitor, Z-VAD-FMK (ZVD).  ZVD globally inhibits all known caspases (ref) 
(46).  ZVD, however, had no effect on IFN-sensitivity of E3LΔ83N.  This suggests that 
del83N induced cell death is caspase independent.  The most well characterized caspase 
independent cell death is programmed necrosis.  Programmed necrosis is dependent on 
the protein kinase, RIP3.  Thus, we asked if a RIP3 specific inhibitor, GSK872, could 
reverse the IFN-sensitivity of E3LΔ83N.  The incorporation of this inhibitor fully rescued 
plaquing efficiency of E3LΔ83N in IFN-treated L929 cells.  This indicated that the IFN-α 
dependent reduction of plaquing efficiency corresponds to a RIP3 dependent mechanism.   
 Global protein loss is dependent on RIP3 and occurs independently of 
caspase activity. In observing GSK872’s ability to recover plaquing efficiency, we 
wanted to determine if it would also rescue the failure to recover protein from E3L∆83N-
infected cells, previously observed.  As seen in Fig. 11, the addition of GSK872 fully 
restored recovery of proteins from IFN-α treated,  E3L∆83N-infected cells. ZVD had no 
effect on the failure to recover proteins from IFN-treated, E3L∆83N-infected cells.  
These results correlated with the plaque reduction assay results and demonstrated that the 
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IFN-α sensitive failure to recover proteins was dependent on RIP3 and independent of 
caspases.  
Alterations in cellular morphologies involving cytoplasmic enlargement and 
membrane disruption dependent on RIP3 occurs independently of caspases.  After 
demonstrating that the IFN-α-associated phenotypes could be rescued with the addition of 
GSK872, signifying the system's dependence on RIP3, we wanted to observe through live 
imaging if GSK872 had an effect on rescuing cell morphology.  Live imaging was 
conducted on untreated VACV-E3L∆83N-infected control cells, IFN-α-treated VACV-
E3L∆83N-infected cells with the addition of GSK872, and IFN-α-treated VACV-
E3L∆83N-infected cells with the addition of ZVD (Fig. 12).  The results of this imaging 
showed that cell morphology was in fact conserved in both untreated VACV-E3L∆83N-
infected control cells and IFN-α-treated VACV-E3L∆83N-infected cells with the addition 
of GSK872.  IFN-α-treated VACV-E3L∆83N-infected cells with the addition of ZVD, on 
the other hand, resulted in cell morphologies as previously observed that were 
characterized by membrane disruption and cytoplasmic enlargment.   
 Inhibition of RIP3 rescues cell viability. The compiled results of the plaque 
reduction assays, Coomassie-blue staining, and live imaging led us to repeat the 
SYTOX© green dye up-take assays.  This time we wanted to include VACV-∆83N + 
GSK872 and VACV-E3L∆83N + ZVD to confirm our prior results (Fig. 13).  The results 
of these assays demonstrated that VACV-E3L∆83N and VACV-E3L∆83N + ZVD 
resulted in decreased cell viability when treated with IFN-α.  This confirmed that the cell 
death occuring was indeed not dependent on caspases.  In contrast, the presence of 
GSK872 in VACV-E3L∆83N-infected cells, rescued cell viability to levels consistent 
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with the MOCK and wtVACV assays performed.  This provided further evidence to 
support the hypothesis that we were observing a form of programmed cell death that was 
dependent on RIP3. 
 VACVs that produce E3L-encoded proteins with truncated N-termini result 
in MLKL activation.  In order to confirm that the cell death was due to a form of 
programed necrosis, the status of MLKL was examined in MOCK, wt VACV, E3L∆83N 
VACV, and TNF cells.  It has been well documented that one of the final steps in 
programmed necrosis involves the aggregation and phosphorylation of MLKL(52).  
Western blots were performed in order to assay for the presence and phosphorylation of 
MLKL (Fig. 14).  TNF+zVAD treatment was used as a positive control(52).  
Phosphorylation of MLKL was demonstrated to occur in L929 cells pretreated with IFN-
α and infected with E3L N-terminal mutants (Fig.14). Phosphorylation of MLKL was 
specific to IFN-α treated and E3L∆83N infected cells and the positive control (Fig. 14C). 
Phosphorylation of MLKL in L929 cells pretreated with IFN-α and infected with VACV 
E3LΔ83N occurred at very early times post infection (3 hpi, Fig. 14B). MLKL also ran as 
an aggregate under non-reducing conditions, in extracts from IFN-treated, E3L∆83N  
infected cells (Fig. 14A).  These results indicate that programed necrosis, involving the 
aggregation and phosphorylation of MLKL, was occurring in IFN-treated E3L∆83N  
infected L929 cells. 
 RIP3 activity is required for IFN-α-sensitive plaque reduction but reduction 
is independent of RIP1. In confirming that cell death was a caspase-independent 
programmed necrosis based on the requirement for RIP3, we also wanted to determine if 
what we were observing was a classical form of necroptosis involving both RIP3 and 
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RIP1 that had been previously described with VACV(25). We therefore evaluated the 
requirements for both RIP1 and RIP3.. To accomplish this, we utilized a RIP1 inhibitor 
known as GSK963 in multiple assays: plaque reduction assay, total protein staining, cell 
viability assay, and MLKL activation.  GSK963 was unable to rescue plaquing efficiency 
(Fig. 15), global protein loss (Fig. 16), cell viability (Fig. 17), or MLKL activation (Fig. 
18) in L929 cells pretreated with IFN-α and infected with VACV-E3LΔ83N. Treatment 
with the RIP3 inhibitor, GSK872, restored IFN-α resistance in all assays. These results 
suggested that we were observing a novel form of programmed necrosis in VACV-
infected cells that is dependent on RIP3 and independent of RIP1. 
 The kinase domain of RIP3 is required for loss of viability. As a further 
measure to evaluate the requirement of a functional RIP3, we conducted a cell viability 
assay utilizing an additional small molecule inhibitor specific to the kinase activity of 
RIP3 (GSK843). Once again, rescue of viability in L929 cells pretreated with IFN-α was 
achieved by treatment with the RIP3 inhibitor GSK872 but not the RIP1 inhibitor 
GSK963, while partial rescue of viability was observed following treatment with the 
RIP3 kinase-specific inhibitor (GSK843) (FIG 19).   
Deficiency of RIP3 rescues VACV-E3LΔ83N pathogenesis in mice. Finally,  
the in vitro results were confirmed in vivo using mouse pathogenesis studies utilizing wt 
C57BL/6 and RIP3 genetically deficient (RIP3-/-) mice. Mice were intranasaly infected 
with 106 PFU of either wt VACV or VACV-E3LΔ83N and monitored for clinical 
symptomology. Wt VACV infections resulted in significant pathology in both types of 
mice. As expected, VACV-E3LΔ83N was apathogenic in wt C57BL/6 mice. 
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Pathogenesis of VACV-E3LΔ83N was restored in RIP3-/- mice to levels equivalent to 
that of wt VACV (Fig. 20).   
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DISCUSSION 
 
 
In this chapter the role of the N-terminal domain of the product of VACV’s 
essential immune evasion gene, E3L, was evaluated. There is overwhelming evidence 
that in VACV, E3 is a potent virulence factor with primary functions involving 
conferring IFN resistance. While the C-terminus of this gene product has been well 
characterized, the function of the N-terminus has remained elusive. While the highly 
conserved nature of this gene product amongst poxviruses implies it provides an essential 
function, for many years no replication phenotype in cells could be identified (Langland 
and Jacobs 2004). To date, the most significant biological phenotype associated with 
deletions of the N-terminus was a 3-4 log loss of virulence in both the intranasal (IN) and 
intracranial (IC) mouse models (81, 111). In both IN and IC models, pathogenesis of 
VACV-E3LΔ83N is fully restored in IFNAR-/- mice, clearly demonstrating that the N-
terminus is required for IFN resistance in vivo (112). The IFN sensitivity of VACV-
E3LΔ83N was found to be mediated by PKR and reproducible in 129 MEFs. 
Surprisingly, this PKR-mediated IFN sensitivity in primary cells did not correspond to 
prior mouse pathogenesis studies, as VACV-E3LΔ83N had maintained a highly 
attenuated phenotype in mice that were genetically deficient in PKR. These findings 
indicated that there is an alternative IFN-regulated programmed cellular death mechanism 
that VACV utilizes the N-terminus of E3 to circumvent.  This process is able to regulate 
in vivo virulence in the absence of the N-terminus of E3.   
 Attempting to gain insight into the function that the N-terminus of E3 plays in 
inhibiting IFN signaling led us to screen murine cell lines for an IFN-sensitive phenotype 
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that could be used to determine the molecular role of the terminus, mimicking previous in 
vivo experiments. A breakthrough came when the murine fibroblast L929 cell line was 
screened. In L929s, VACV expressing E3 protein with truncated N-termini (VACV-
E3LΔ83N) were highly IFN-sensitive and VACV expressing full length E3 was able to 
replicate in the presence of high doses of IFN. The IFN sensitivity of VACV-E3LΔ83N 
was demonstrated through a plaque reduction assay. L929 cells were pretreated with 
increasing amounts of mouse IFN-α to promote an antiviral state and were subsequently 
infected with VACV-E3LΔ83N or wt VACV.  VACV-E3LΔ83N-infected cells that were 
pretreated with IFN-α were unable to form plaques in a logarithmic, IFN-α dose-
dependent manner with a 50% reduction in plaquing efficiency seen at an IFN-α 
concentration between 3 and 10 U/ml.  Wt VACV retained an IFN-resistant phenotype, 
shown by its ability to form plaques even at the highest dose of IFN-α. The IFN-sensitive 
phenotype observed in VACV-E3LΔ83N-infected L929 cells indicated that they may be 
a viable system for evaluating the biochemical function of the N-terminus of E3.  
  Regulation of translation is a common antiviral mechanism that can be influenced 
by IFN signaling.  During viral infections, the activation of PKR leads to phosphorylation 
of the alpha subunit of translation initiation factor eIF2.  This phosphorylation results in 
protein synthesis shut off, thereby preventing virus replication (119, 120). VACV-
E3LΔ83N has been shown to lead to late activation of PKR in some cells in culture, 
demonstrating that the N-terminal domain is necessary for full initiation of PKR.  
However, unlike what is seen following classical PKR activation, this late activation does 
not inhibit late viral protein synthesis or inhibit viral replication (110). 
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To gain further insight into whether translational regulation was contributing to 
IFN sensitivity, protein synthesis was evaluated by radiolabeling proteins with 
[35S]methionine at multiple times post infection.  This evaluation demonstrated that when 
VACV is deleted of E3L (VACVΔE3L), infections result in the loss of [35S]methionine 
incorporation, regardless of IFN treatment.  This was seen by 6 HPI and signified early 
recognition of viral infection.  The loss of [35S]methionine incorporation in VACVΔE3L 
corresponded to a pattern of protein synthesis termination demonstrated through 
Coomassie staining. Cells that were treated with IFN-α and infected with 
VACVE3LΔ83N also demonstrated a reduction of [35S]methionine incorporation. 
Unexpectedly, there was a corresponding global protein reduction that was not previously 
noted in VACVΔE3L-infected cells.   Additionally, this reduction was IFN-dependent 
and inhibited by wt VACV infections. This phenomenon demonstrated a novel phenotype 
that was potentially an unexplored IFN-regulated mechanism to control viral infections. 
 The newly observed phenotype involving a global protein loss in an IFN-
dependent manner over the course of infections with VACVE3LΔ83N in L929 cells 
caused us to question the structural modifications that could account for this loss of total 
cellular protein.  Live imaging of L929 cells that were pretreated with IFN-α and infected 
with VACV expressing E3 N-terminus mutants suggests that total protein loss may be 
attributed to a loss of membrane integrity. L929 infected with VACVE3LΔ83N following 
treatment of IFN-α demonstrated dramatic alterations in morphology; most notable of 
these changes were membrane blebbing and cytoplasmic enlargement occurring at early 
time points post infection. These early alterations in morphology suggested that the cells 
might be induced to undergo rapid programmed cell death through mechanisms not 
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typically seen in apoptosis.   To evaluate if the morphology observed was due to a 
cellular death mechanism, a cell viability assay was performed.  Morphology changes 
observed did correlate to cellular death.  This further suggested that the N-terminus of E3 
functions to inhibit an IFN-primed programmed cell death. 
 While the apoptosis form of programmed cell death has long been recognized as a 
host strategy to restrict viral infections, alternative forms have been recently identified 
through the study of cell-intrinsic mechanisms to regulate viral infections. To determine 
whether the IFN-primed cell death induced in the absence of the E3 N-terminus was 
apoptosis or another characterized mechanism of programmed cell death, a series of 
inhibitors were employed to target critical proteins in apoptosis, pyroptosis, and 
programmed necrosis. Through the use of a pan-caspase inhibitor we demonstrated that 
the IFN-sensitive phenotype of VACV-E3LΔ83N in L929 cells was not due to caspase-
dependent mechanisms of programmed cell death, which excluded both pyroptosis and 
apoptosis as the cause of death.  The inhibition of caspases was not able to rescue 
plaquing efficiency, global protein loss, alterations in morphology or cell viability. 
Instead, cell death seemed to be attributed to a programmed necrotic death, as an inhibitor 
targeting RIP3, an essential protein in the programmed necrosis pathway, was able to 
restore IFN resistance. In the presence of the RIP3 inhibitor, assays with VACV-
E3LΔ83N infections demonstrated results that were equivalent to results with wt VACV 
infections. Induction of programmed necrosis was subsequently confirmed through the 
demonstration of MLKL activation and through the utilization of an additional inhibitor 
specific to the kinase activity of RIP3, which prevented the reduction in cell viability.  
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These results are consistent with necrotic death, as both MLKL activation and the 
utilization of RIP3 are hallmarks of this form of programmed cell death. 
 A pivotal moment for uncovering programmed necrosis as a host defense 
mechanism came with the discovery that VACV-infected cells treated with TNF were 
able to undergo a RIP3 kinase-dependent programmed necrosis. More important, mice 
lacking RIP3 were unable to utilize programmed necrosis, making them more susceptible 
to VACV infections (25). Induction of programmed necrosis was demonstrated to be 
dependent on a functioning VACV-encoded caspase inhibitor and to signal through 
canonical necroptosis, which involves RIP1:RIP3 interactions utilizing RHIM domains 
after TNF induces death receptor activation (25). 
 Previous studies have shown that VACV is capable of inducing programmed 
necrosis in the presence of TNF; this induction, however, is dependent on both RIP1 and 
RIP3, although other RHIM-containing proteins have also emerged as adaptor proteins 
for RIP3 activation (27, 44, 46, 117).  In follow-up to these studies, we decided to 
evaluate the requirement of RIP1 in the VACVE3LΔ83N-induced programmed necrosis 
to gain better insight into how the E3 N-terminus may function to prohibit cell death. 
Utilizing a small molecule inhibitor specific to RIP1, we demonstrated that 
VACVE3LΔ83N-infected L929 cells treated with IFN-α are able to undergo 
programmed necrosis independently of RIP1 activity. This represents a unique pathway 
of programmed necrosis induction by VACV that implicates a regulatory mechanism 
beyond the previously described function of a caspase inhibitor.  
 It has been suggested that programmed necrosis may represent the default cell 
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death pathway utilized when caspases inhibitors are encoded by pathogens (29). 
However, in addition to the requirement for a pathogen-encoded caspase inhibitor, the 
infected cells must also express sufficient levels of RIP3 (51, 52). Consequently, the 
biological significance of RIP3-dependent programmed necrosis induced by VACV-
E3LΔ83N required us to examine in vivo models. Mice genetically deficient in RIP3 
were used to demonstrate that the IFN-regulated programmed necrotic death in VACV-
E3LΔ83N-infected L929 cells corresponded to biological significance in vivo.  In C57B6 
mice ,VACV-E3LΔ83N infections were apathogenic.  In RIP3-deficient mice, however, 
pathogenesis was equivalent to that of wt VACV. 
 This study has provided significant insight into the biological role that the N-
terminus of E3 plays in evading the host IFN system.  It can be concluded from these 
results that the N-terminus of E3 is required to prevent the initiation of an IFN-primed, 
virally induced programmed necrosis.  Additionally, the induction of programmed 
necrosis represents a unique pathway not previously described in VACV infections, as it 
occurs independently of RIP1.  This shows that with the rapidly evolving field of 
pathogen-associated programmed necrosis, VACV could offer a valuable tool to 
investigate non-canonical pathways and mechanisms for pathogen regulation.  
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Figure 5.  Schematic of E3 N-terminal truncation mutants. The two main forms of 
E3 that wt VACV generates is depicted with full length E3 at the top followed by the 
truncated P20 E3 naturally produced during infection.  Below the wt versions of E3 
are truncation mutants generated by deleting the first 37 (E3L∆37N)  or the first 83 
amino acids (E3L∆83N). 
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Figure 6. IFN-sensitivity plaque reduction assay. Assay was preformed by 
pretreating a monolayer of L929 cells with increasing concentrations of mouse IFN-α 
for 18 hours prior to infection. VACV with wtE3 was IFN resistant but truncation of 
the E3 N-terminus (VACV-E3LΔ83N) resulted in an IFN-sensitive virus, with a 50% 
reduction occurring between 3 and 10 units/ml. The percent of original plaque 
forming units (PFUs) is plotted against the dosage of IFN-α Units (U)/mL utilizing 
both wt VACV (blue) and mutated VACV producing E3 proteins with truncated N-
termini (red). 
 
  50 
 
Figure 7. Evaluation of protein synthesis and total cellular proteins L929 cells 
were pretreated with 100U/ml of mouse IFN-α (based on previously determined 
inhibitory concentration) for 18 hours prior to infection. Cells were then infected with 
Mock, wt, and VACV expressing E3L mutants at an MOI of 5. Infected cells were 
then starved at for 1 hr, pulsed with [35S]methionine for 30 min and then harvested. 
Proteins from equal cell volumes were separated on 10% SDS-PAGE gels. (A)  
Radiolabeled proteins were analysed by autoradiography; (B) Total protein was 
evaluated by Coomassie blue staining. Samples pretreated with IFN and infected with 
VACV-E3LΔ83N demonstrated a significant global reduction in protein.  
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Figure 8. Morphological changes in L929 cells following infection. Transmitted 
live imaging at 6 HPI of L929 cells pretreated with 100U/ml of mouse IFN-α and 
then infected with an MOI of 5 of mock, wt VACV, or VACV-E3LΔ83N. IFN-
treated cells infected with VACV-E3LΔ83N underwent drastic changes in 
morphology that is atypical for classical cytopathic effect (CPE) or apoptosis.  
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Figure 9. Loss of viability in IFN-sensitive N-terminal truncation mutants: Cell 
viability was determined using SYTOX© green dye uptake assays utilizing the average 
viable cells observed in 10 fields 5 HPI . (A) Loss of membrane integrity and cell death 
is indicated by the uptake of both dyes (green). (B) The percent of viable cells 5 hpi are 
compiled from the SYTOX© green dye uptake assays performed.  These percentages 
are plotted for each cell group (wt VACV, VACV-E3L∆83N, and MOCK) for 0 U/mL 
IFN-α pretreatments (blue) and 100 U/mL IFN-α pretreatments  (red). IFN-sensitive 
VACV expressing N-terminal E3 mutants undergo a rapid loss of membrane integrity 
and cellular death. 
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Figure 10. Rescue of plaguing efficiency by inhibiting RIP3. Plaque reduction 
assay was performed by pretreating L929 cells with increasing amounts of mouse 
IFN-α for 18 hours prior to infection. Cells were then treated with 100µM of a RIP3 
inhibitor (GKS872),  or 50µM of a pan-caspase inhibitor (ZVD) or mock-treated 
(DMSO) for 1 hour prior to infection. Cells were then infected with equivalent PFU of 
wt VACV or VACV-E3LΔ83N and plaque  were allowed to form and the percent of 
PFU reduction was calculated. IFN resistance was not restored in cells treated with 
ZVD but was restored by treatment with GKS872.  
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Figure 11. Rescue of global protein loss by inhibiting RIP3.  Coomassie blue 
staining of total protein lysates following pretreatment of L929 cells treated with 
100U/ml and infected with control VACV-E3L∆83N at an MOI of 5. Evaluation for 
reduction of total protein  for untreated control VACV-E3L∆83N cells, IFN-α-treated 
VACV-E3L∆83N-infected cells, IFN-α-treated VACV-E3L∆83N-infected cells with 
the addition of GSK872, and IFN-α-treated VACV-E3L∆83N-infected cells with the 
addition of ZVD.  Lower amounts of Commassie staining correlate to higher global 
protein loss. 
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Figure 12. Rescue of morphological changes by inhibiting RIP3. Transmitted live 
Imaging at 6 HPIof L929 cells pretreated with 100U/ml of mouse IFN-α for 18 hours 
and for one hour with either mock, ZVD-FMK or GKS872 prior to infection and then 
infected with VACV-E3LΔ83N at an MOI of 5. Ghost cell morphology is inhibited by 
the treatment of GKS872 but not ZVD.  
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Figure 13. Rescue of cell viability by inhibiting RIP3. The percent of viable cells was 
evaluated at 5 hpi SYTOX© green dye uptake assay. Values are based on the average 
of 10 fields of view at 20X magnification. These percentages are plotted for each cell 
group  (MOCK, wt VACV, VACV-E3L∆83N, VACV-E3L∆83N+GSK872, and 
VACV-E3L∆83N+ZVD) for 0 U/mL IFN-α pretreatments (blue) and 100 U/mL IFN-α 
pretreatments (red). 
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Figure 14. Western blot detection of MLKL phosphorylation. Western blots were 
performed for the detection of MLKL and its phosphorylation. (A) MLKL and 
phosphorylated MLKL expressions are shown for MOCK, wt VACV, VACV-
E3L∆83N, and TNF positive control samples under both untreated and 100 U/mL 
IFN-α-treated conditions. Phosphorylation of MLKL is specific to VACV-E3L∆83N 
in IFN-α-treated cells. (B) The MLKL and phosphorylated MLKL expressions are 
shown for VACV-E3L∆83N from 1-5 hours post infection. MLKL activation is 
observed as early as 3 hpi. (C) Aggregated total MLKL expression levels are shown 
under non-reducing conditions, demonstrating activation by oligomerization as seen 
by a shift. MLKL aggregation is specific to VACV-E3L∆83N in IFN-α-treated cells. 
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Figure 15. Rescue of plaquing efficiency is rescued by inhibiting RIP3 but not 
RIP1.  The percent of original plaque forming units (PFUs) is plotted against the 
dosage of  IFN-α Units (U)/mL utilizing wt VACV (blue), VACV-E3L∆83N(red), 
VACV-E3L∆83Nwith GSK872 (green), and VACV-E3L∆83N with GSK963 
(purple).   
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Figure 16. Rescue of total protein loss by inhibition of RIP3 but not RIP1. Cells 
were either treated with or without IFN and either mock-infected , infected with 
VACV-E3LΔ83N or were treated with ZVD plus TNFα . For lanes 5 and 8, cells were 
treated with a RIP3 inhibitor, GSK872, while for lanes 6 and 9, cells were treated with 
a RIP1 inhibitor, GSK963. Only the RIP3-specific inhibitor prevents protein release in 
VACV-E3LΔ83N-infected cells, while both inhibitors prevent protein release in cells 
treated with ZVD and TNFα. 
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Figure 17.  Cell viability rescue by inhibiting RIP3 but not RIP1. The percent of 
viable cells 5 hours post transfection (make consistent) are compiled from the 
SYTOX© green  dye uptake assays performed.  These percentages are plotted for each 
cell group  (MOCK, wt VACV, VACV-E3L∆83N, VACV-E3L∆83N+GSK872, and 
VACV-E3L∆83N+GSK963) for 0 U/mL IFN-α pretreatments (blue) and 100 U/mL 
IFN-α pretreatments (red). 
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Figure 18. Phosphorylation of MLKL is prevented by inhibiting RIP3.  A Western 
blot was performed to check for MLKL and phosphorylated MLKL expression.  The 
blot was performed for both untreated and IFN-treated MOCK and VACV-E3L∆83N-
infected cells in addition to TNF treated cells with additional MOCK, GSK 872, and 
GSK 963 treatments. 
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Figure 19. Rescue of cell viability by inhibiting RIP3 but not RIP1.  A cell 
viability assay was performed using a cell titer glow cell viability assay in L929 cells 
pretreated for 18 hours with IFN-α. Cells were then treated with DMSO (mock), 
GSK963 (RIP1 inhibitor), GSK872 (RIP3 inhibitor), or GSK843 (RIP3 kinase-
specific inhibitor). Cells were infected with  mock, wt VACV, VACV-E3LΔ83N, or 
TNF ZVD (positive control for RIP1-, RIP3-dependent death).  Relative cell viability 
is measured  in relative luminescence units (RLUs) at 12 hours post-
infection/treatment.  
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Figure 20. RIP3 deficiency restores pathogenesis of VACV-E3LΔ83N. 8-10-
week-old C57BL/6 mice were infected by intranasal route with 106 PFU of the 
indicated viruses. Clinical scores (based on multiple symptoms) indicate that wt 
VACV is pathogenic in the mice, beginning at 6 days post-infection (DPI) while 
VACV-E3LΔ83N remains non-pathogenic throughout the experiment. However, in 
mice with homozygous disruption of the RIP3 gene, the pathogenesis of VACV-
E3LΔ83N parallels that of wt VACV. 
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CHAPTER 3 
VACCINIA VIRUS-INDUCED PROGRAMMED NECROSIS IS REGULATED BY 
 Z-NA BINDING PROTEINS 
ABSTRACT 
The N-terminus of E3 encoded by VACV has been demonstrated to be essential for 
inhibiting a RIP1-independent programmed necrosis that is regulated by type I 
interferons. The N-terminus shares homology to the family of Z-DNA binding proteins 
that includes ADAR-1 and DAI. Prior studies have demonstrated substitution of the N-
terminus of E3 with distantly related Z-DNA binding domains fully complements 
pathogenesis of VACV. Additionally, point mutations that decrease the affinity of Z-
DNA binding also correlate to a decrease in VACV pathogenesis in mice. Together, these 
results suggest that a functional Z-DNA binding domain of E3 is necessary for full 
pathogenesis. In this study the cytosolic DNA sensor, DAI, is implicated as the adaptor 
protein for RIP3 activation in programmed necrosis resulting from infections with VACV 
lacking a functional E3 Z-DNA binding domain. Expression of both RIP3 and DAI are 
required to induce programmed necrosis in vitro. The highly attenuated phenotype of 
VACV with E3 Z-DNA binding domain mutations is reversed in mice genetically 
deficient of DAI. Furthermore, induction of programmed necrosis was dependent on the 
presence of a functional Z-DNA binding domain in DAI and the absence of a functional 
Z-DNA binding domain in E3. These results grant novel insight into the elusive functions 
of the E3L Z-DNA-binding domain. Together, they suggest that Z-NA may be 
recognized as a PAMP by DAI and is sequestered from recognition by the VACV-
encoded Z-DNA-binding domain of E3. 
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INTRODUCTION 
 
In investigating the role the N-terminus of E3 plays in inhibiting an IFN-primed 
programmed necrosis, indications of its function can be inferred by the homology 
between E3 and a family of Z-form nucleic acid (Z-NA) binding proteins. Several prior 
studies have indicated that Z-NA binding plays a role in the induction of the IFN 
pathway. Both mammalian proteins ADAR1 and DNA-induced activator of interferon 
(DAI) are regulated by IFN and contain Z-NA-binding domains (Z-NA-BD) (96, 102). In 
mammalian systems, DAI has been identified as a cytosolic sensor capable of 
recognizing dsDNA and activates the IFN pathway (108, 121). The Z-NA-BD of E3 is 
highly conserved among orthopoxviruses, and shares structural homology to a family of 
Z-DNA-binding proteins, such as IFN-inducible ADAR-1 and DAI (108, 121). However, 
the presence of Z-NA-BD is not restricted to mammalian cultures. Fish encode PKZ, a 
PKR-like protein that contains a Z-NA-BD in place of the dsRNA binding domains found 
in human PKR (122). The PKZ protein has been implicated in host pathogen defense 
mechanisms. PKZ can be upregulated following immune stimulation resulting in the 
phosphorylation of eIF2α.  Together, these findings suggest that Z-NA binding has a role 
in the host response to viral infections.  
Since the identification of Z-NA-BDs, there has been significant interest in 
uncovering their role in binding nucleic acids in the left-handed configuration (Z-NA). 
An even more confounding question is if the presence of Z-NA in a cell contributes to 
host immune responses to pathogens such as VACV. Recent studies of VACV E3 
demonstrated that deletion of the Z-NA-BD results in significant loss of viral 
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pathogenicity (105). Additionally, site-directed mutagenesis of key Z-NA binding 
residues that decreased binding affinity for Z-NA corresponded to a decrease in 
neurovirulance (105). The Z-NA-BD and, more specifically, the regions required for Z-
NA binding are essential for virulence.  
Further evidence to support the role the N-terminus has as a Z-NA-BD and its 
significance in pathogenesis was provided by domain-swapping studies where the Z-NA-
BD of E3 was replaced with a Z-NA-BD from one of two distantly related Z-DNA 
binding proteins, ADAR-1 and DAI. Despite having very limited sequence homology 
outside of amino acid residues that make contact with Z-NA, Z-NA-BD chimeric viruses 
fully complemented the pathogenesis and retained lethality in intracranial infections 
(105). Furthermore, point mutations that diminish Z-NA binding in chimeras decrease the 
pathogenicity of the virus equivalent to the attenuation seen in the Z-NA-BD point 
mutations in E3 (105). 
During viral infections, early detection is essential for initiating an innate immune 
response and protecting the host organism. Viral nucleic acids recognized as an essential 
PAMP are also recognized by PRR for the activation of the innate immune response 
(123). DAI has been demonstrated to act as a cytosolic DNA sensor that can initiate an 
innate immune response independent of the well-established endosomic DNA sensor, 
TLR 9 (108, 121). DAI has been shown to recognize foreign DNA and upregulate type I 
IFN in addition to the initiating other immune responses.  
DAI is a multifunctional protein that can be IFN-upregulated or constitutively 
expressed depending on tissue type.  It is composed of 3 nucleic acid-binding domains: a 
RHIM domain and two additional RHIM-like repeats (28, 117). Consistent with the other 
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members of the Z-NA-binding protein family, the Z-NA-BDs are located within the N-
terminus. DAI contains tandem Z-NA-BDs termed ZαDAI and ZβDAI. The third nucleic 
acid binding domain (D3) is located next to the ZβDAI, and is unique from the first two 
binding domains;  D3 is reported to bind right-handed B-DNA (108). The N-terminal 
region, including D3, is thought to be essential for sensing multiple forms of DNA. DAI 
has been shown to be able to bind both Z and synthetic B forms of DNA (108). Binding 
of DNA activates DAI, inducing the C-terminus to bind to the serine/threonine kinase, 
Tank binding kinase 1 (TBK1), and the transcription factor, IFN regulatory factor 3 
(IRF3) (108). Evidence has established that all three nucleic acid binding domains are 
essential for full activation of the DNA-dependent immune response (121). Additionally, 
DAI induction of the innate immune responses may require that DAI dimerizes (121). 
Interestingly, the Z-NA-BDs of DAI contribute to stress granule localization similarly to 
that of E3 (124). 
DAI belongs to a family of Z-NA-binding proteins that are found in a diverse 
array of organisms. Some of the best studied examples include the vertebrate ADAR1, 
the fish protein kinase containing Z-DNA-binding domains (PKZ) and the viral E3 of 
poxviruses. Biochemically, they can all tightly and specifically bind to Z-DNA. Based on 
the orientation of the binding residues, many of them also have the capacity to convert B-
DNA to Z-DNA (123). Despite a lack of sequence homology, a common binding mode to 
the left-handed orientation is achieved through a consistent structure paired with a few 
highly conserved residues that are involved in DNA binding. The conserved positively 
charged or polar residues confer specificity to the unique zig-zag conformation of the Z-
DNA backbone. This conservation of binding residues can be seen with a protein 
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sequence alignment of the Z-NA-BD of E3 and the ZαmDAI. E3 contains seven out of the 
nine conserved residues necessary for binding to Z-DNA. While there are many water-
mediated hydrogen-bonds supporting Z-DNA interactions with the binding pocket, the 
interactions between tyrosine and the C8 of guanine oriented in a SYN conformation is 
essential for conferring the specificity to Z-DNA binding (97). The structural homology 
found within the Z-NA-BD consists of 3 β-strands and 3 α-helices (123). Z-NA-BDs 
recognize Z-DNA with conformational specificity through the α helix (α3) and the wing, 
which is made up mostly of an antiparallel β-sheet involving β2 and β3 and a β-loop 
(123). The ZαDAI  is considered a canonical Z-NA-BD and maintains high specificity to 
Z-DNA. The ZβDAI domain has also been shown to bind Z-NA; however, it also has the 
ability to bind and convert B-DNA to Z-DNA (123). 
In Chapter One we demonstrated that the Z-NA-BD located in the N-terminus of 
E3 is required to inhibit an IFN-regulated programmed necrosis. This form of VACV-
induced programmed necrosis occurred in a RIP1-independent fashion in contrast to 
findings that originally implicated necrotic death as an alternate host defense pathway 
against VACV (25).  In classical programmed necrosis, RIP3 utilizes RIP1 as an adaptor 
protein to initiate the signal transduction cascade leading to MLKL phosphorylation and 
subsequent cell death. The formation of the RIP3, RIP1 complex is achieved through the 
interaction of RHIM domains found on both proteins.  Additional RHIM-containing 
proteins have been implicated to function as adaptor proteins of RIP3 in the induction of 
non-classical programmed necrosis. DAI, and TIR-domain-containing adapter-inducing 
interferon β (TRIF) both contain RHIM domains and can interact with RIP3 to initiate 
programmed necrosis. In particular, DAI has been shown to be a sensor of multiple 
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members of the herpes virus family infection used in the induction of programmed 
necrosis (4).  
Until the recent discovery that the Z-NA-BD of E3 is required to inhibit an IFN-
regulated programmed necrosis, the molecular mechanism by which it conferred IFN 
resistance was unknown.  However, due to the homology between the ZαDAI and the Z-
NA-BD of E3, both having the capacity to bind Z-NA, it was hypothesized that E3 may 
act as a competitive inhibitor of the host-encoded Z-NA binding proteins (23). 
Additionally, it has been proposed that DNA-mediated oligomerization of DAI 
contributes to the activation of the innate immune response (5). It is possible that VACV 
E3 competes with DAI for the binding to Z-NA, thereby preventing activation of the 
innate immune response or induction of programmed necrosis.   
In this chapter we investigate DAI as an alternative adaptor protein of RIP3 in the 
induction of VACV-induced programmed necrosis. Additionally, we investigate the 
requirement for a functional Z-NA-BD of both E3 and DAI. 
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MATERIALS AND METHODS 
 
 
RT-PCR Methods. RNA was isolated from mock or IFN-treated cells at 18 hours 
post-treatment using Qiagen’s Rneasy Mini Kit (74104) with the optional on-column 
DNase digestion (79254). 500ng of RNA was then reverse transcribed into cDNA using 
PrimeScript™ RT reagent Kit (Takara, RR037A). Samples were amplified using 
PrimeTime® Gene Expression Master Mix (IDT, 1055772) on a CFX Connect™ Real-
Time PCR Detection System (BioRad, 1855201). Predesigned primer sets were 
purchased from IDT; order numbers are as follows: DAI (Mm.PT.58.21951435), RIP1 
(Mm.Pt.58.9721411), RIP3 (Mm.PT.58.33227794), MLKL (Mm.PT.58.16870825), 
GAPDH (Mm.PT.39a.1). Fold induction of genes was determined using the ΔΔCq 
method with GAPDH as the control gene and untreated cells as mock. 
Immunoblotting: Protein extraction and Western immunoblot analysis. L929 
cells were pretreated with 100 U/mL of mouse IFN-α (Calbiochem) for 18 hours. If 
indicated as infected, cells were infected with viruses at an MOI of 5. L929 infected cells 
were harvested at 4 HPI. Cells were scraped into medium and subsequently pelleted by 
centrifugation at 500 × g for 10 min at 4°C to extract lysates. The supernatant was 
removed, and the cells were washed, pelleted, and washed a second time with ice-cold 
PBS. Cells lysates were then obtained by lysing the cells in complete Triton X lysis 
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
Na3VO4, and 1X Halt Protease and Phosphotase Inhibitor Cocktail, Pierce Thermo 
Scientific) and incubated on ice for 5 min. Samples were centrifuged at 15,000 × g for 20 
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min at 4°C. Supernatant was collected and SDS protein loading dye (3X) was added. All 
samples were stored at -80°C. Samples were boiled for 5 min, separated on a denaturing 
10% SDS-PAGE gel, and then transferred onto a nitrocellulose membrane at 100 volts 
for 60 min in 10 mM CAPS, pH 11 with 20% methanol. Following transfer, the 
membrane was incubated in blocking buffer (140 mM NaCl, 3 mM KCl, 20 mM Tris [pH 
7.8], 0.05% Tween 20, 3% nonfat milk) for 1 hour at room temperature. Rabbit 
polyclonal antibodies were used to detect P-MLKL (Abcam, 1:2000) and total MLKL 
(Abcam, 1:1000), Z DNA binding protein 1(DAI) (Abcam, 1:1000), RIP3 (Abcam, 
1:2000), RIP1 (BD, 1:1000) and mouse monoclonal antibodies were used to detect 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primary antibodies were diluted 
in blocking buffer and blots were exposed to antibodies overnight at ratios specified. 
Secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (1:10,000, Santa 
Cruz) or anti-mouse IgG conjugated to horseradish peroxidase (1:10,000, Santa Cruz) 
were incubated at room temperature for 1 hour. Immunoreactive bands were visualized 
by chemiluminescent development using SuperSignal West Dura Duration substrate 
(Pierce Biotechnology).  
Cells and viruses and Treatments. L929 cells were maintained in minimum 
essential medium (MEM) supplemented with 5% fetal bovine serum (FBS, HyClone) and 
not allowed to exceed 7 passages. L929 cells were treated with indicated concentrations 
of  mouse IFN-α (Calbiochem) for 18 h prior to infection.  HEK293T cells were 
maintained in Dulbecco's modified minimum essential medium (D-MEM) supplemented 
with 10% HI FBS. Cells used as a positive control for programmed necrosis were treated 
with TNF-α (Sigma) (L929: mouse TNF-α  at 20ng/ml; HEK293T: human TNF-α  at 
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50ng/ml) following a 1-hour pretreatment with 100µM of ZVD (ApexBio).Viruses were 
previously generated using the WR strain of VACV by methods previously described 
(81). E3 N-terminal mutations include an N-terminal truncation (VACV-E3LΔ83N). 
Point mutation viruses include a loss of Z-NA binding mutant (VACV-E3L-P63A) and a 
negative control (VACV-E3L-E42A) that retains the Z-NA binding capacity. Chimeric 
viruses were generated as previously described by replacing the Z-NA-BD of E3 
(Nucleotides 61-261, representing amino acids 1 to 67 of the vaccinia virus E3L gene 
product (S64006) with either the Zα domain of DAI (VACV-E3L-ZαmDAI, nucleotides 
116-316  of AF136520) or ADAR1 (VACV-E3L-ZαhADAR1,  nucleotides 554-742 of 
U10439 ). All virus stocks were grown in BHK cells. Crude virus stocks were purified by 
pelleting through a 36% sucrose pad and confirmed by sequencing.  
Expression of DAI and RIP3 in HEK 293T . The human RIP3 and DAI or 
mutant versions of the proteins were expressed from plasmid expression systems in HEK 
293T cells that inherently lack both proteins.  The following plasmids were generously 
donated by Ed Mocarski (Emory University) and Jason Upton (University of Texas): 
p3XFLAG-CMV-10 (empty vector),  p3XFLAG-CMV-10 (Hs) WT RIP3, p3XFLAG-
CMV-10 (Hs), wt DAI,  p3XFLAG-CMV-10,  MutRHIM-A 
(Hs,DAI(I206QIG209→A206AAA209))(Sac2),  p3XFLAG-CMV-10 DAI ΔZα(Hs 
DAI(78-429), p3XFLAG-CMV-10 DAI ΔZαβ (Hs DAI(170-449)), p3XFLAG-CMV-10 
mutZα (Hs DAI N46D/Y50A) (BcII), p3XFLAG-CMV-10 mutZβ (Hs DAI 
N141D/Y145A) (Mscl). Plasmids were constructed using p3XFLAG-CMV-10 with cut 
sites of BgIII and Xbal. Sequences were confirmed  using the N-CMV-30 primer (5'-
AAT-GTC-GTA-ATA-ACC-CCG-CCC-CGT-TGA-CGC-3’)  and   C-CMV-24 (5’-
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TAT-TAG-GAC-AAG-GCT-GGT-GGG-CAC-3’). Plasmids were transformed into One 
Shot® TOP 10 chemically competent E. coli (Invitrogen) according to manufacturer’s 
instructions and incubated on ampicillin-LB agar plates at 37oC overnight. Transformed 
bacteria were cultured in Terrific Broth (TB) containing ampicillin. Plasmids were 
isolated using a Maxi Prep Kit (Qiagen). Plasmids were transfected into HEK 293T cells 
using X-treme GENE™ HP DNA Transfection Reagent (Sigma) according to 
manufacturer’s instructions.  At 48 hours post transfection, if indicated, the cells were 
treated as described below and infected at an MOI of 5 with the indicatedvirus. 
Mouse Intranasal Infections of Mice. Anesthesia and infections were carried out 
as previously described (81). Briefly, wt C57B6 and mice genetically deficient of DAI  
(ZBP-1 -/-)  mice were anesthetized with a ketamine cocktail containing 37.5 mg/ml 
ketamine (Lloyd Laboratories, Shenandoah, IA), 7.5 mg/ml xylazine (Vedco, St. Joseph, 
MO), and 2.5 mg/ml acepromazine maleate (Fort Dodge Laboratories, Fort Dodge, IA) at 
the age of 8 to 10 weeks. Intraperitoneal injection (IP) of anesthesia was given at a dose 
of 1 µl per gram of body weight. Anesthetized mice were infected with 5 µl containing 
106 PFU of either WR strain of wt VACV or VACV-E3LΔ83N virus intranasally. Mice 
were monitored daily for clinical signs and given a clinical score based on weight loss, 
lethargy, respiratory distress, decline in general appearance (scruffed), and eye infections. 
Each clinical sign was given a score of 1 to 5 with 5 representing sever symptomology. 
Weight loss score was determined by the percent of their original weigh  with 100% of 
original weight receiving a score of 0; 93.7 to 99.9% given a score of 1; 86.2 to 93.2% 
given a score of 2; 78.6 to 86.1% given a score of 3; 71.0 to 78.5%  given a score of 4; 
and 70% and below was given a score of 5 (81, 111). All mice were euthanized by 
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asphyxiation using CO2 when any mouse dropped below 30% of their initial weight or 
reached a clinical score above 25. Generation of DAI point mutant. Generation of point 
mutations were constructed by whole plasmid PCR mutagenesis using overlapping 
primers as previously described (92). Briefly, 100ng p3XFLAG-CMV-10 (Hs) WT DAI  
was then used as a DNA template in whole plasmid PCR. 500 µM hDAI ZαP63A F 
primer ( 5'- GTCTCCCTCACATCCGCAGCCACCTGGTGCTT -3'), 500 µM hDAI 
ZαP63A R primer (5’ -AAGCACCAGGTGGCTGCGGATGTGAGGGAGAC-3’), 500 
µM dNTPs, 2 mM MgSO4, 1X Pfx buffer, 1X Enhancer and Platinum pfx polymerase 
enzyme (Invitrogen) were mixed in a 25 µL reaction volume. PCR amplifications were 
performed with 95ºC for 3 minutes, followed by 18 cycles of amplification (95ºC for 15 
seconds, 52ºC for 1 minute, 72ºC for 12 minutes). Primers were designed to generate 
p3XFLAG-CMV-10 hDAI ZαP63A containing a site specific point mutation in the DAI 
Zα domain of the Z-NA binding residue corresponding to the point mutation found in 
VACV E3L-P63A. Samples were subject to restriction digests overnight at 37 ºC by 
DPN1 using Cutsmart buffer (NEB) and DPN1 (NEB). Following digest, sample was 
ethanol precipitated with 2.5 volumes of 95% ethanol, 0.1 volume of 7.5M ammonium 
acetate, and 10µL glycogen (Fermentas). The DNA was washed in 70% ethanol, dried 
and resuspended in 10µL of distilled water. One Shot® TOP 10 chemically competent E. 
coli (Invitrogen) cells were transformed with p3XFLAG-CMV-10 hDAI ZαP63A 
according to manufacturer’s instructions and incubated on ampicillin-LB agar plates at 
37oC overnight. Isolated colonies were selected; plasmid DNA was extracted using the 
PureYield TM Plasmid MiniPrep System (Promega) and the DNA was resuspended in 50 
µL nuclease free water (Invitrogen). Mutation was confirmed by sequencing.  
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Interferon resistance evaluation by plaque reduction.  6-well plates of 
subconfluent L929 cell monolayers were treated with 0-300 U/mL of mouse IFN-α 
(Calbiochem) 18 hours prior to infection. Cells were then infected with approximately 
100 PFU of the indicated virus diluted in MEM containing 2% FBS in a volume of 100 
µL. Cells were incubated at 37oC, 5% CO2 for 1 hour, with rocking every 10 minutes.  
After 1 hour, cells were overlaid with of MEM containing 5% FBS, and incubated at 
37ºC.  Following the formation of plaques, approximately 48-72 hpi, the monolayers 
were stained with crystal violet (0.5 % in 20% ethanol) and plaques were counted.  The 
reduction in the number of plaques was recorded as a percentage of plaques in the 
absence of interferon and was plotted against increasing units of interferon. 
SYTOX® nuclear stain uptake viability assay.  L929 cells were plated in 12-
well CytoOne tissue culture treated plates (USA Scientific) at a confluency of 35% and 
pretreated with 100 U/mL of mouse IFN-α (Calbiochem) for 18 hours prior to infection. 
Cells were incubated with Hoechst 33342 dye for 15 minutes prior to infection. If 
indicated, cells were pretreated for 1 hour prior to infection and subsequently infected 
with an MOI of 5 with the indicated virus. At 5 , SYTOX® Green nucleic acid stain 
(Thermo Fisher Scientific) was added to the medium  at a concentration of 1 µM and 
allowed to incubate for 15 minutes. Percent of viable cells was determined by calculating 
the average number of cells that were double-stained for Hoechst and SYTOX compared 
to the total number of cells present in each field. The average viability was calculated 
from a total of 10 fields using a 20X objective of 20X on an EVOS™ FL Auto Imaging 
System ( Invitrogen™).   
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CellTiter-Glo® Luminescent Cell Viability Assay (Promega). HEK293T cells 
were plated in a 96-well plate and transfected and treated as described above. Cells were  
infected with the indicated virus as described above at an MOI of 5. At 12 HPI, CellTiter-
Glo reagent was according to manufacture's recommendations and incubated at room 
temperature for 30 minutes. Results were read on a GloMax® 96 Microplate 
Luminometer (Promega) as relative luminesce units (RLU).  
Protein staining. 50% confluent L929 cell monolayers in 60 mm dishes were 
infected with WR strains of wt VACV or with VACV expressing the indicated E3 N-
terminal mutants at a MOI of 5. At 12 HPI, cells were washed twice with pre-warmed 
PBS, then pelleted and lysed in 100 µL of 1X SDS (62.5 mM Tris-Cl, 10% glycerol, 2% 
SDS, 0.0005% bromophenol blue, 0.1% 2-mercaptoethanol, 1X Halt Protease and 
Phosphotase Inhibitor Cocktail, Pierce Thermo Scientific). Protein lysates were isolated 
utilizing QIA Shredder columns (Qiagen) by spinning lysates in columns at 16,000xg for 
2 minutes at 4oC. Samples were stored at -80°C. The samples were boiled for 5 minutes 
and separated on denaturing 10% SDS-PAGE gels. The gels were stained for total protein 
levels with Coomassie staining solution (0.1% Coomassie Brilliant Blue R-250, 40% 
methanol and 10% glacial acetic acid) for 30 minutes, then were destained with 
destaining solution (40% methanol and 10% glacial acetic acid) three times, each 20 
minutes, and incubated overnight in 10% glacial acetic acid to remove any residual stain. 
 
Sequencing of the E3L recombinant virus mutants.  Virus DNA was extracted 
by treating an aliquot of the virus stock with a 1:1 ratio of  virus and phenol equilibrated 
with 10 mM Tris HCl, pH 8.0, 1 mM EDTA (Sigma).  Subsequently the aqueous phase of 
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the sample was re-extracted with equal volumes of phenol:isoamylalcohol:chloroform 
(25:24:1) (Sigma). The aqueous phase from the above step was re-extracted once again 
with an equal volume of chloroform:isoamylalcohol (24:1) (Sigma), followed by 
precipitation as described above. 
Gene amplification was preformed using PCR with E3L flanking primers to 
amplify the gene for sequencing.  Briefly, 100 ng of virus DNA template, 500 µM of E3L 
F,  500 µM of E3L R, 500 µM dNTPs, 2 mM MgSO4, 1X Pfx buffer, 1X Enhancer and 
Platinum pfx polymerase enzyme (Invitrogen) were mixed in a 50 µL reaction volume.  
PCR amplifications were performed with 95ºC for 5 minutes, followed by 30 cycles of 
amplification (95ºC for 1 minute, 55ºC for 1 minute, 68ºC for 5 minutes).  PCR product 
was separated by agarose gel electrophoresis (0.8%, GTG grade). DNA was extracted 
from the gel using Wizard® SV Gel and PCR Clean up Kit (Promega) according to the 
manufacturer’s instructions, and sequenced.  
Statistics. Statistical analysis was done by using a two-tailed, unpaired T test. P 
values of p<0.001 were represented as ***, p<0.01 were represented as **,  p<0.05 were 
represented as * and no significance (N.S.) was used to represent p>0.05 
  78 
RESULTS 
 
DAI is upregulated in L929 cells following IFN-α  treatment. The IFN-α-sensitive 
phenotype of VACV-E3LΔ83N in L929 cells is due to the induction of programmed 
necrosis. Under these conditions, programmed necrosis occurs independently of RIP1. 
RIP1 functions as the adaptor protein for RIP3 activation in the classical programmed 
necrosis pathway; but because we had determined that RIP1 is not involved in the 
induction of death  in this system, we sought to identify the adaptor protein being utilized 
in its place. Several other RHIM-containing proteins have been shown to interact with 
RIP3 to induce programmed necrosis. Upon review of other known RIP3 adaptor 
proteins, DAI emerged as a potential candidate because it contains a homologous Z-NA-
BD to the one deleted in VACV-E3LΔ83N. Induction of programmed necrosis in L929 
cells by VACV-E3LΔ83N requires the treatment of IFN-α. Therefore, we decided to 
evaluate if DAI expression was induced following IFN-α treatment. In addition to DAI, 
other important proteins in the programmed necrosis signaling pathway were examined 
including RIP1, RIP3, and MLKL. Alterations in transcript levels were evaluated by 
qPCR normalized to GAPDH. No significant changes of transcript levels were observed 
in RIP1, RIP3, or MLKL following IFN-α treatment. Treatment of L929 cells with IFN-
α resulted in a significant induction of DAI with greater than a 3-log induction (Fig21A). 
Protein levels of RIP1, RIP3, MLKL, and DAI were also evaluated for changes 
corresponding to IFN-α treatment of L929 cells by Western blotting. An increase in the 
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protein level of DAI was observed in IFN-α-treated L929 cells (Fig. 21B). No substantial 
changes were noted in the other three proteins that were evaluated.  
DAI is required for the induction of programmed necrosis by VACV-E3LΔ83N. 
Expression of DAI was demonstrated to be significantly increased in L929 cells 
following IFN-α treatment. Due to the diversity of ISGs we wanted to determine if DAI 
expression, in the absence of IFN stimulation, was sufficient to induce susceptibility to 
programmed necrosis in cells infected with VACVE3LΔ83N. HEK293T cells express 
RIP1 but are deficient in both RIP3 and DAI. Utilizing a plasmid expression system, we 
induced the expression of either RIP3 alone or in combinations with DAI in HEK293T 
cells. Following transfections, cells were either treated with TNF-α and a caspase 
inhibitor(ZVD) or infected with wt VACV or VACVE3LΔ83N. In the presence ZVD, 
TNF-α activates the classical programmed necrosis signaling cascade involving RIP1 and 
RIP3. Expression of RIP3 was sufficient to sensitize the HEK293T cells to programmed 
necrosis following treatment with TNF-α and ZVD. Expression of RIP3 alone was not 
sufficient to sensitize the cells to VACVE3LΔ83N induced death. The expression of both 
RIP3 and DAI was required for the induction of programmed necrosis in 
VACVE3LΔ83N infected cells(Fig. 22). Wt VACV was unable to induce death in any 
condition tested. This implicated DAI as the adaptor protein for RIP3 in programmed 
necrosis induced by VACVE3LΔ83N.   
Deficiency of DAI(ZBP1-/-) rescues pathogenesis of VACV E3LΔ83N in mice. 
The initial indication that the N-terminus of E3L is essential and conferred IFN resistance 
was demonstrated by a 3 log reduction in pathogenesis in mice. VACVE3LΔ83N  is 
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apathogenic in wt C57BL/6 mice but has equivalent pathogenesis to wt VACV in 
IFNRα/β-/- mice. Evidence thus far suggests that the IFN sensitive phenotype of 
VACVE3LΔ83N is due to the induction of an IFN primed programmed necrosis. We 
have shown that in the absence of RIP3 VACVE3LΔ83N is as pathogenic as wt VACV 
implicating programmed necrosis as a host defense mechanism in VACVE3LΔ83N 
infections. In order to further evaluate DAI as the candidate adaptor protein required for 
RIP3 activation we conducted an in vivo pathogenesis study. IN infections were done in 
C57BL/6 and mice genetically deficient for DAI(ZBP1-/-) mice with VACVE3LΔ83N or 
wt VACV. As expected VACVE3LΔ83N was highly attenuated in C57BL/6 mice. 
VACVE3LΔ83N pathogenesis was restored in  in ZBP1-/- mice(Fig.23).  
The Zα domain of DAI is required for the induction of programmed necrosis by 
VACV E3LΔ83N. The presence of homologous Z-NA-BD found both in the full length 
E3L and in DAI lead to the hypothesis that the Z-NA-BD found in the N-terminus my 
function to bind to and sequester a PAMP form being sensed by the Z-NA-BD(ZαDAI) of 
DAI. However, DAI is a multidimensional protein with numerous interaction domains. 
The ZαDAI domain of DAI shares the greatest homology to the E3L Z-NA-BD and is 
specific for binding left handed DNA(102, 123).  The ZβDAI is also able to bind Z-NA but 
with less specificity as it is also known to bind right handed(B-DNA). The D domain 
binds B-DNA exclusively. Lastly DAI contains three RHIM domains in the C-terminus 
with RHIM-A predicted to be the most important for the induction of programmed 
necrosis through its interaction with RIP3(125). Therefore we wanted to evaluate which 
binding domain was utilized in VACVE3LΔ83N induced programmed necrosis. In order 
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to accomplish this, we once again utilized an expression system in HEK293T cells with 
plasmids containing domain specific mutations. Cells were transfected with RIP3 and 
DAI mutants and then infected with VACVE3LΔ83N. Any cells expressing mutations in 
the ZαDAI were resistant to VACVE3LΔ83N induced death. Expression of mutations 
ZβDAI were susceptible to VACVE3LΔ83N induced death(Fig.24). Additionally it was 
shown that VACVE3LΔ83N induced death was dependent on a functional RIP3 RHIM 
and the RHIM-A of DAI(Fig24). This RHIM dependent pattern is consistent with the 
previous studies of herpesvirus family induced programmed necrosis. Together these 
results indicate that functional RHIM domains in both RIP3 and DAI and the ZαDAI are 
required for VACVE3LΔ83N induced programmed necrosis. 
IFN-α sensitivity and programmed necrosis is due to the loss of Z-NA binding 
domain function in E3L. Programmed necrosis in VACV infections appears to be 
competitively regulated by two distantly related proteins that both encode a Z-NA-BD in 
their N-terminus. Our data suggest that the Z-NA-BD of E3L is required to suppress 
programmed necrosis while the ZαDAI is necessary for its induction. Although both Z-
NA-BD are structurally similar, very little sequence homology is present. The exception 
to the absence of sequence homology is the presence of a few highly conserved residues. 
The conserved residues found in both Z-NA-BD are responsible and necessary for 
conferring binding specificity to Z-NA(105). Our data thus far suggests that a 
competitive regulation of VACV induced programmed necrosis between the ZαDAI and 
the E3L Z-NA-BD.  We therefore hypothesize that the regulation of VACV induced 
programmed necrosis maps to the conserved Z-NA binding residues. In order to evaluate 
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VACV E3L mutants were generated containing site specific point mutations. VACVE3L-
P63A contains a point mutation required for Z-NA binding and is therefore a loss of 
function mutant.  VACV E3L-E42A was generated as a control point mutant. In 
VACVE3L-E42A the mutated residue is located outside of the binding pocket and does 
not make contact with Z-NA therefore it retains its binding function. We sought to 
evaluate if a disruption in Z-NA binding is responsible for the original phenotypes 
observed in VACVE3LΔ83N induced programmed necrosis. In order to evaluate this 
L929 cells were pretreated with IFN-α to induce the expression of DAI and infected with 
the VACV E3L point mutates. The loss of Z-NA binding function point mutant had 
phenotypes consistent with a full truncation of the E3L N-terminus. In L929 cells 
pretreated with IFN-α, the loss of function point mutant resulted in a dose dependent 
reduction of plaquing efficiency (Fig26), cytoplasmic enlargement and membrane 
blebbing(Fig.27), global protein loss(Fig. 28), reduction in viability(Fig29) and 
phosphorylation of MLKL(Fig. 30).  The control point mutant that retained the Z-NA 
binding mirrored the phenotype of wt VACV. Together these findings indicate that the 
IFN-α primed programmed necrosis in VACV infections is due to the loss of the ability 
to bind to Z-NA.  
Z-NA-BD chimeric viruses rescue IFN sensitivity and prevent programmed 
necrosis. Domain swapping experiments were conducted to confirm that the IFN-α 
primed programmed necrosis induced by VACV mutants corresponds to Z-NA binding 
function. Chimera viruses were generated by exchanging the Z-NA-BD of E3L with the 
Zα domains of two distantly related Z-NA binding proteins including the human 
ADAR1(VACVE3L-ZαhADAR1) and mouse DAI(VACVE3L-ZαmDAI). Z-NA-BD 
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swapping fully compensated for the Z-NA-BD of E3L and was able to inhibit the 
induction of programmed necrosis equivalent to wt VACV. Chimeric viruses retained 
their plaquing efficiency indicating IFN-α resistance (Fig31). There was no significant 
loss of viability at early times post infection(Fig32). Finally, chimera viruses did not 
induce MLKL phosphorylation in IFN-α treated L929 cells(Fig33).  Once again this data 
suggest that the capacity to bind to Z-NA is required to inhibit the IFN-α primed 
programmed necrosis in VACV infected cells.  
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DISCUSSION 
 
In this study we investigated the role of the Z-NA-BD of E3L in regulating an IFN-
primed programmed necrosis. Our previous work demonstrated that VACV encoding for 
a E3L protein lacking the Z-NA-BD(VACV E3LΔ83N) was highly attenuated as a result 
of a rapid induction of a RIP3-dependent programmed necrotic death following infection 
in IFN-treated cells. However, this death occurred independently of RIP1, which is 
required as the adaptor protein in the classical necroptosis pathway. To gain insight into 
both the function of the E3 Z-NA-BD and the alternative pathway used in VACV-
induced programmed necrosis we turned our attention back to the highly conserved Z-
NA-BD motif.  
E3 is an essential innate immune evasion protein that confers IFN resistance. 
While the C-terminus has been well characterized in its role of binding and sequestering 
dsRNA, the function of the conserved N-terminus has remained elusive. The N-terminal 
half of E3 is a member of the Zα family of Z-NA binding proteins (106).  Other members 
of this family include the Zα domains of  ADAR1 (96) and DAI (93). These three Z-NA-
BDs have a conserved structure consisting of a helix-turn-helix motif with an additional 
β-sheet.  The structures of ZαADAR1, ZαDAI  and Z-NA-BD of E3 are very similar; 
however, the amino acid sequence is not conserved outside of the residues that make 
contact with Z-NA (105). Seven of the nine residues found in the other members of  this 
family that are involved in the interaction with Z-DNA are conserved in the N-terminus 
of E3 (105). 
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The functional and structural homology between the Z-NA-BD of E3 and the Zα 
domain of DAI led us to investigate the possibility of DAI as an alternative RIP3 adaptor 
protein in VACV-induced programmed necrosis. DAI has previously been demonstrated 
to initiate a RIP1-independent programmed necrosis in several herpesvirus infections. In 
these herpesvirus models of programmed necrosis, DAI utilizes its C-terminal RHIM 
domain to interact and activate RIP3, thereby inducing the signal cascade leading to death 
(29, 46). 
Induction of programmed necrosis in VACV lacking a Z-NA-BD in the E3 
protein was dependent on IFN stimulations prior to infection. The requirement for IFN 
stimulation signifies that the mechanisms involved with the induction of death utilizes an 
ISG. Therefore, we sought to determine if our primary candidate, DAI, was upregulated 
in response to IFN stimulation in L929 cells. Our results demonstrated that DAI is 
upregulated in L292 cells (Fig. 21). Furthermore, we demonstrated that ectopic 
expression of  RIP3 and DAI was sufficient to evoke susceptibility to VACV-E3LΔ83N-
induced programmed necrosis in the absence of IFN stimulation (Fig. 22).   
Confirmation of the significant role that DAI plays in the highly attenuated and 
IFN-sensitive phenotype of VACV-E3LΔ83N was further established by pathogenesis 
studies. IN infections demonstrated that VACV-E3LΔ83N is apathogenic in mice 
expressing DAI in contrast to the highly pathogenic wt VACV. However, pathogenesis 
was fully restored in mice genetically deficient in DAI (Fig.23) and mirrored the rescue 
of pathogenesis seen in RIP3-/- mice previously shown in chapter 1 (Fig. 20).  Together 
this data implicated DAI as the RIP3 adaptor protein used in VACV-E3LΔ83N induced 
programmed necrosis.  
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The requirement of DAI in programmed necrosis induced by VACV lacking a Z-
NA-BD was highly suggestive that the Z-NA binding may have a significant biological 
role in the viral host interaction. Because DAI and the Z-NA-BD of E3 are both members 
of the Zα family of Z-NA-binding proteins, our investigation turned to evaluating the role 
that Z-NA-binding ability plays in the induction of programmed necrosis. While DAI is a 
member of the Zα family, it also consists of multiple domains that are not involved with 
the Z-NA-binding function. Therefore, we wanted to determine if the domains specific to 
Z-NA binding in DAI were required for its role in VACV induced programmed necrosis. 
Through the use of ectopic expression of  DAI containing mutations or deletions of 
various domains we demonstrated that a functional Zα domain was required for death to 
be induced (Fig. 24). The Zα domain of DAI is specific to Z-NA binding and its 
requirement confirmed that the Z-NA-binding ability plays an important role in VACV-
induced programmed necrosis.  
VACV expressing a full length E3 is resistant to DAI-regulated programmed 
necrosis, but deletion of the Z-NA-BD of E3L sensitized it death induction. Since the 
ability of DAI to bind Z-NA is required for VACV-E3LΔ83N-induced programmed 
necrosis we then sought to evaluate if the inhibition of death by full length E3 was a 
function of its ability to bind Z-NA.  Z-NA binding by E3 is predicted to require seven 
highly conserved residues (16-mat). A VACV E3 point mutant that lacks the ability to 
bind to Z-NA was generated to evaluate the requirement of a functional Z-NA-BD for the 
inhibition of programmed necrosis. The disruption of Z-NA binding in E3 induced by a 
single residue change resulted in a phenotype and propensity to induce an IFN-primed 
programmed necrosis equivalent to that of VACV-E3LΔE3L.  Thus, the function of the 
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N-terminus of E3 to inhibit a DAI-driven programmed necrosis corresponds specifically 
to its ability to bind to Z-NA.  
As a final measure to evaluate Z-NA-binding function to regulate VACV-induced 
programmed necrosis, we asked if Z-NA-BD of distantly related members of the Zα 
protein family could functionally replace the one found in E3. While the general Z-NA-
BD structure is conserved,  the amino acid sequences have very little homology within  
the Zα family outside of the residues used to contact Z-NA. VACV E3L chimera viruses 
were generated by replacing the coding for the Z-NA-BD of E3 with either that of the Zα 
domain from mouse DAI or human ADAR1. E3 Zα chimera viruses were as efficient as 
wt VACV in inhibiting programmed necrosis. The uses of these viruses confirmed that 
the ability to inhibit programmed necrosis in VACV-infected cells was specific to the 
ability to bind Z-NA.  
This work demonstrated that the N-terminal Z-NA-BD of E3 functions to inhibit a 
DAI-driven programmed necrosis. The ability of E3- to inhibit programmed necrosis 
depends on its ability to bind to Z-NA. Additionally, the induction of VACV-induced 
programmed necrosis in the absence of the Z-NA-BD of E3 requires a functional Zα 
domain of DAI, which has specificity for binding Z-NA. This dynamic interplay between 
two Z-NA binding proteins in the regulation of VACV-induced programmed necrosis 
suggests they work in a competitive fashion. This regulation of VACV-induced 
programmed necrosis by two opposing, competing Z-NA-binding proteins illuminates the 
possibility that Z-NA may play a biologically significant role as a PAMP during VACV 
infections, with  E3 functioning to sequester it to prevent sensing by DAI.  
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Figure 21. IFN-α regulation of DAI expression in L929 cells. The expression of DAI, 
RIP1, RIP3, and MLKL is determined after 100 U/mL IFN-α treatments for 18 hours in 
L929 cells. (A) Transcript levels are measured using qPCR. (B) Protein expression 
levels are measured byWestern blot analysis.  
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Figure 22. VACV-induced programmed necrosis requires both RIP3 and DAI. 
Viability of human 293T cells under indicated conditions was measured by Cell 
Titer-Glo Assay at 12 hours post infection/treatment. 293T cells are deficient in RIP3 
and DAI. Ectopic expression of RIP3 sensitizes cells to TNF+ZVD treatment, but not 
VACV-E3LΔ83N infection. Ectopic expression of RIP3 and DAI sensitizes cells to 
VACV-E3LΔ83N infection. The viability of cells infected with either MOCK, wt 
VACV, or VACV-E3LΔ83N, or treated with TNF+ZVD is measured in relative 
luminescence units under RIP3- and DAI-deficient conditions, RIP3-expressing and 
DAI-deficient conditions or and RIP3- and DAI-expressing conditions.  
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Figure 23. Rescue of VACV-E3LΔ83N pathogenesis in ZBP1-/- mice. 8-10-week-
old C57BL/6 mice were infected by intranasal route with 106 PFU of the indicated 
viruses. Clinical scores (based on multiple symptoms) indicated that wt VACV is 
pathogenic in the C57BL/6mice, while VACV-E3LΔ83N was not. However, in mice 
with a homozygous disruption of the ZBP-1 (DAI/DLM) gene, VACV-E3LΔ83N 
becomes pathogenic. 
 
  91 
 
 
3500000
4000000
4500000
5000000
5500000
6000000
Vector
w
t D
A
I
w
t R
IP
3
w
t R
IP
3
m
ut R
H
IM
 
R
IP
3
m
ut R
H
IM
-A 
D
A
I
delZA 
delZA
B
m
utZA D
A
I
m
utZB
 D
A
I
Re
la
tiv
e	
Ce
ll	
Vi
ab
ili
ty
	(R
LU
)
Cell	Viability	
Single Plasmid 
+ wt. DAI
+ wt. RIP3
***
***
Mutations of the Za domain of DAI Rescuers Viability in 
E3LΔ83N Infected Cells.
Z-NA BD dsRBME3L
DAI RHIM A RHIM B RHIM CDZa Zβ
Figure 24. Mutations of the Za domain of DAI rescues viability.  Cell viability 
assays were performed utilizing a plasmid expression system in HEK293T cells.  
Control transfection (single) vector, DAI, or RIP3 (green).  Cell viability assays were 
then performed utilizing DAI in combination with RIP3 and DAI in combination with 
RIP3 with a mutated RHIM domain (blue).  Lastly, viability assays are performed 
using RIP3 in combination with DAI with a mutated RHIM-A domain, deleted Zα 
domain, deleted Zα and Zβ domains, mutated Zα domains, and mutated Zβ domains. 
Viability was assed using a Cell Titer Glow Assay following a 12-hour infection with 
VACV-E3LΔ83N.  
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                                                      **  **  *             *** * 
E3LVaccinia    5 YIDERSNAEIVCEAIKTI-GIEGATAAQLTRQLNME-KREVNKALYDLQRSAMVYSSDDIPPRWFMTT 70 
E3LVariola     5 YIDERSDAEIVCEAIKNI-GLEGVTAVQLTRQLNME-KREVNKALYDLQRSAMVYSSDDIPPRWFMTT 70 
ZαADAR1      134 SIYQDQEQRIL-KFLEELGEGKATTAHDLSGKLGT-PKKEINRVLYSLAKKGKLQKEAGTPPLWKIAV 199 
ZαMDAI         9 STGDNLEQKIL-QVLSDDGG--PVKIGQLVKKCQV-PKKTLNQVLYRLKKEDRVS—-SPEPATWSIGG 70 
ZαHDAI         9 GREGHLEQRIL-QVLTEAGS--PVKLAQLVKECQA-PKRELNQVLYRMKKELKVS--LTSPATWCLGG 70 
Figure 25. Schematic of E3 Z-NA binding domain and generated mutants. (A) E3 is a 
25 kDa protein. In the N-terminus is the Z-NA-binding domain that has several distinct 
residues that can bind to Z-form nucleic acid including Z-DNA or Z-RNA. (B) To insure the 
phenotypes observed are specific to the loss of Z-NA binding, a point mutation was 
generated of a predicted key Z-NA-binding residue (E3L_P63A). Additionally a control 
point mutant was generated that has a mutated residue outside the predicted interacting 
regions of the domain (E3L_E42A).  
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Figure 26. Disruption of E3 Z-NA binding results in IFN sensitivity in L929 
cells. Plaque reduction assay using Z-NA-binding domain point mutants was 
performed by pretreating L929 cells with increasing amounts of mouse IFN-α for 18 
hours prior to infection. The P63A and Y48A  point mutations in the Z-NA-binding 
domain of E3 results in disruption of binding. E42A is a negative control point 
mutation located outside the binding domain. Loss of Z-NA-binding function 
resulted in equivalent IFN sensitivity as that of VACV-E3LΔ83N, while the control 
point mutant retained IFN resistance equivalent to wt.  
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Figure 27. Alterations in morphology is specific to loss of Z-NA binding function 
in E3. Transmitted live imaging at 6 HPI of L929 cells pretreated for 18 hours with 
100U/ml of mouse IFN-α followed by infection with E3LΔ83N, E3L-P63, or E3L-
E42A at an MOI of 5. Ghost cell morphology is specific to IFN-treated cells and the 
loss of a functional Z-NA binding domain. 
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Figure 28. Global protein loss is due to loss of Z-NA binding.  L929 cells were 
pretreated with 100 U/ml of mouse IFN-α for 18 hours prior to infection. Cells were 
then infected with mock, wt VACV, E3LΔ83N, E3L-P63A, and E3L-E42A at an MOI 
of 5. A total protein gel was utilized to demonstrate the global cellular proteins in both 
IFN-α treated and untreated cells. Samples pretreated with IFN and infected with E3 
mutants with a loss of Z-NA-binding ability demonstrated a significant global 
reduction in protein. 
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Figure 29. Loss of viability corresponds to the loss of the ability of E3 to bind Z-
NA . The percent of viable cells 5 hours post transfection are compiled from the 
SYTOX© green dye up-take assays performed. Cell viability was determined using an 
average of viable cells in 10 fields These percentages were plotted for each infected 
cell group  (MOCK, wt VACV,VACV- E3L∆83N, VACV-VACVE3L-P63A, and 
VACV-E3L-E42A) for 0 U/mL IFN-α pretreatments (blue) and 100 U/mL IFN-α 
pretreatments (red). Induction of rapid cell death is consistent with the loss of Z-NA 
binding and IFN sensitivity. N-terminal mutants with disrupted Z-NA binding 
capacity consistently induce a rapid loss of membrane integrity and cellular death. 
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Figure 30. Inhibition of MLKL activation requires E3 Z-NA binding. A Western 
blot was performed to check for MLKL and phosphorylated MLKL expression.  The 
blot was performed for both untreated and IFN-treated MOCK, VACV-E3L∆83N, 
VACV-E3L-P63A, and VACV-E3L-E42A cells infected cells.  TNF+ZVD-treated 
cells were added as a positive control. MLKL phosphorylation corresponds to the 
loss of Z-NA binding.  
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E3LVariola     5 YIDERSDAEIVCEAIKNI-GLEGVTAVQLTRQLNME-KREVNKALYDLQRSAMVYSSDDIPPRWFMTT 70 
ZαADAR1      134 SIYQDQEQRIL-KFLEELGEGKATTAHDLSGKLGT-PKKEINRVLYSLAKKGKLQKEAGTPPLWKIAV 199 
ZαMDAI         9 STGDNLEQKIL-QVLSDDGG--PVKIGQLVKKCQV-PKKTLNQVLYRLKKEDRVS—-SPEPATWSIGG 70 
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Figure 31. E3 Z-NA binding residues are conserved in the Zα domain of DAI. 
(A) Sequence alignment of the Z-NA-BD of E3, mouse and human DAI normalized 
by length. Green signifies 70% conservation and corresponds to residues required for 
Z-NA binding.  (B) A schematic of the organization of the protein domains for E3, 
DAI, ADAR1 (p150). (C) A schematic of VACV domain-swapping chimera viruses 
generated by replacing the N-terminus of E3 with the Zα domains of either human 
ADAR1 (E3LZαhADAR1) or mouse DAI (E3LZα mDAI ). 
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Figure 32. Zα functionally replaces the E3 Z-NA-BD for plaquing efficiency. 
Plaque reduction assay was performed by pretreating L929 cells with increasing 
amounts of mouse IFN-α for 18 hours prior to infection. Cells were infected with 
equivalent PFUs and allowed to form plaques.  The percent of original plaque 
forming units (PFUs) is plotted against the dosage of  IFN-α Units (U)/mL utilizing 
wt VACV (blue), VACV-E3L∆83N (brown), VACV-E3LZαmDAI (purple), and 
VACV-E3LZαhADAR1 (green). Viruses expressing any version of a functional Z-NA-
BDZ-NA-BD are IFN-α resistant.  
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Figure 33. The Zα of DAI or ADAR1 functionally replaces the E3 Z-NA-BD to 
inhibit loss of cell viability.  The percent of viable cells 5 hours post transfection 
were compiled from the SYTOX© green dye uptake assays performed.  These 
percentages were plotted for each infected cell group  (MOCK, wt VACV, VACV-
E3L∆83N, VACV-E3LZαmDAI, and VACV-E3LZαhADAR1) for 0 U/mL IFN-α 
pretreatments (blue) and 100 U/mL IFN-α pretreatments (red). Presence of a 
functional Z-NA-BD prevents induction of cell death.  
 
  101 
 
 
 
- + - + - + -
M
oc
k
M
oc
k
E3
LΔ
83
N
E3
LZ
α h
A
D
A
R
1
w
t.
VA
C
V
E3
LΔ
83
N
IFN-α
P-MLKL
MLKL
+- +
w
t.
VA
C
V
E3
LZ
α h
A
D
A
R
1
E3
LZ
α m
D
A
I
E3
LZ
α m
D
A
I
E3L Z-NA Binding Domain Chimera Viruses Inhibit MLKL 
Phosphorylation 
E3LZαmDAI
dsRBMZaE3LZαhADAR1
dsRBMZa
Z-NA BD dsRBME3L
L929 lysates harvested at 4HPI
Figure 34. E3 Z-NA-BD chimera viruses do not induce MLKL phosphorylation   
A Western blot was performed to check for MLKL and phosphorylated MLKL 
expression.  The blot was performed for both untreated and IFN-treated MOCK, wt 
VACV, VACV-E3L∆83N, VACV-E3LZαhADAR1, and VACV-E3LZαmDAI infected 
cells. Presence of a functional Z-NA-BD inhibits programmed necrosis.  
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CHAPTER 4 
OVERALL DISCUSSION  
 
In this study, the role of the Z-NA-binding domain located in the N-terminus of 
E3 on type I IFN-primed programmed necrosis inhibition was investigated.  This was 
done through initially studying L929 cells.  It was found that wt VACV was IFNresistant 
and could effectively replicate in the presence or absence of IFN. However, when VACV 
was modified to produce E3 proteins with truncated N-termini, a rapid IFN-primed cell 
death was induced. These results led us to question the role of both the N-terminus of E3 
and the mechanisms involved in the induction of programmed cell death. 
Programmed necrosis was identified as a method of cell death to investigate 
further. Because previous work had also demonstrated that RIP3 is an essential protein 
for inducing programmed necrosis, we decided to inhibit RIP3 activity through the RIP3 
kinase inhibitor GSK872.  Inhibition of the RIP3 activity in cells infected with the 
previously attenuated mutant VACV restored viral replication, even in the presence of  
interferon.The rescue of IFN sensitivity supported the hypothesis that the cell death 
previously examined was indeed programmed necrosis.  To confirm this hypothesis, 
MLKL activation, which takes place in the last step of programmed necrosis, was 
confirmed in IFN+ cultures infected with the modified VACV. Phosphorylation levels in 
the assay were sufficient to establish that MLKL activation was occurring.  This result in 
combination with the results of RIP3 inhibition on cell cultures confirmed that the 
previous cell death observed was in fact due to programmed necrosis. 
In order to determine which host proteins have roles integral to programmed 
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necrosis, we researched the literature to identify candidates that have been known to 
initiate the process.  Through this research, the protein DAI came up as the prime 
candidate for a RIP3 adaptor protein.  Consequently, we analyzed DAI levels in both 
IFN+ and IFN- cultures through qPCR and Western blots.  The results of these 
characterization experiments showed that DAI was absent in IFN- cells, but upregulated 
in IFN+ cells.  This led us to investigate HEK293T cells, which were known to be 
deficient of both RIP3 and DAI.  No cell death was observed in these cells through either 
TNF treatment (the classical necroptosis pathway) or through infection with the modified 
VACV However, expression of RIP3 through transfection, recover the formation of 
RIP1-RIP3 complexes, which then induced cell death.  On the other hand, addition of 
RIP3 to the cells was not sufficient to recover VACV-E3LΔ83N-induced programmed 
necrosis; this induction required the addition of DAI in conjunction with RIP3 to cultures.  
These results demonstrated that cell death through programmed necrosis is heavily 
dependent on both RIP3 and DAI. Confirmation of the biological relevance of RIP3 and 
DAI in VACV infections was demonstrated through pathogenesis studies. Intranasal 
infection with VACV containing E3 N-terminal mutations are apathogenic; however, in 
mice genetically deficient of either RIP3 or DAI (ZBP1-/-), the pathogenesis was rescued 
to wt VACV levels. 
Since both E3 and DAI are members of the same Zα family, we wanted to 
determine if the Z-NA-binding function was required on both proteins.  A previous 
domain swapping study of the Z-NA binding domain of the N-terminus of E3 with other 
Z-NA-binding domains (Zα DAI or ZαADAR1)  demonstrated that despite having less 
than 20% sequence homology to the E3 Z-NA-BD,  the Zα domains functionally replace 
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the Z-NA-BD of E3(105, 106, 126). The results of this study demonstrated that replacing 
Z-NA binding domains in E3 had no significant effect on the performance of VACV.  
Additionally, further evidence to support the requirements of a functional Z-NA-BD in 
E3 is seen by a loss of pathogenesis corresponding to any disruption of the Z-NA binding 
(105). 
These results led us to further investigate the effect of a potential Z-NA-binding 
domain in E3 on programmed necrosis.  By utilizing the HEK293T system, the domains 
of DAI required to initiate programmed necrosis were evaluated. It was found that the Zα 
domain confers specificity to Z-NA binding, and along with RHIM domain A, was 
required for the induction of death. In order to investigate the Z-NA-binding role of E3, 
we artificially induced point mutations in key residues of E3 responsible for coding the 
possible Z-NA-BD on E3.  Incorporation of these point mutations resulted in a substantial 
attenuation of the modified VACV phenotype in IFN+ cultures that was not observed in 
wild type.  This result demonstrated that the previous cell loss observed in IFN+ cells 
infected with the E3 N-terminus mutant of VACV was due to the missing Z-NA-binding 
domain that resulted from truncation.  From this finding, we were able to determine that 
the Z-NA-binding domain of E3 has a significant effect on the inhibition of programmed 
necrosis for VACV. 
A compilation of this data shows that the N-terminus of E3 plays a critical role in 
inhibiting the IFN-primed and virally-induced programmed necrosis that is dependent on 
both the RIP3 kinase domain and the Z-DNA-binding host protein DAI. Since the N-
terminus contains a Zα domain that is functionally replaceable by the Zα domain of DAI 
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and the ability to bind to Z-NA is required by both proteins in this system, we 
hypothesize that the N-terminus of E3 functions in inhibition of necroptosis by inhibiting 
DAI.  Induction of necroptosis correlates with loss of Z-NA binding of the N-terminus, 
suggesting that the N-terminus of E3 may compete with DAI for binding to a viral or host 
macromolecule that DAI senses to induce necroptosis. Viral inhibition of DAI has 
previously been demonstrated in the herpesvirus system through the use of a competitive 
RHIM inhibitor. However, E3 inhibition is likely a novel mechanism of inhibition as it 
does not contain an identifiable RHIM domain.  
Further characterization of the E3 and DAI function during VACV infection 
could provide significant insight into signaling events leading to RIP3-dependent 
necrosis. It will also provide a greater understanding of the use of programmed necrosis 
as an innate host defense mechanism. The rapid induction of this highly inflammatory 
death occurs prior to late viral protein synthesis stages and therefore may provide 
valuable insight into adaptive immune responses and insight into safer vaccine 
development.  
Since our results suggest that the Z-nucleic acid-binding function of the N-
terminus of E3 is important for inhibition of induction of necroptosis, and since the Zα-
containing protein DAI has been implicated in sensing virus infection, this work may 
have the potential to evaluate Z-NA as a possible PAMP.  Enhanced understanding of the 
role of the Z-NA-BD in E3 can provide insight into the pathogenesis of monkeypox 
virus, as it contains a natural truncation in the N-terminal Zα domain of its E3 homologue 
(80, 109).   
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Recently, programmed necrosis has been identified as an important pathway in 
the field of oncology. Many cancers have been shown to have low RIP3 expression, 
thereby reducing their susceptibility to programmed necrosis (127). Currently 
myxomavirus, which lacks a Zα domain on its E3 homologue, is in testing in humans as 
an oncolytic virus. Investigating how the presence or absence of  Zα domains in 
relationship to RIP3 level could provide significant insight into the engineering of 
effective oncolytic viruses.  
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Figure 35.  Summary figure. Schematic of the main components of the signaling 
cascade involved with the alternative form of programmed necrosis is shown for 
cells infected with either VACV-E3L∆83N or wt VACV. The VACV-encoded E3 
Z-NA-BD functions to prevent the activation of programmed necrosis, utilizing 
DAI as an adaptor protein for RIP3. In the absence of a functional Z-NA-BD in E3, 
DAI is believed to function as a PRR and sense Z-NA as a PAMP. In the presence 
of full length E3 the Z-NA is believed to be sequestered by E3 to prevent detection 
by DAI.   
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